粘附分子与UAP中医证候相关规律及黄芪多糖干预机理研究
|
摘要
目的
以统计学和数据挖掘方法,从冠心病不稳定性心绞痛患者临床信息中归纳证候类型和证候要素,并研究其与血清中粘附分子P-选择素,VCAM-1浓度变化的关系,从无监督的机器分析数据方法中,获得较客观的更深层次隐含关系。
通过对人心脏微血管内皮细胞(HCMEC)进行缺糖缺氧和复糖复氧造模,模拟心绞痛发作时缺血对血管内皮的损伤机制,研究黄芪多糖对内皮损伤时粘附分子(P-选择素,VCAM-1)表达的干预作用和对P38和NF-Kb通路的信号转导机制。
方法
1.运用Kohonen网络聚类方法,对265例不稳定性心绞痛(UAP)患者的临床症状聚类分析,获得不稳定性心绞痛(UAP)的临床常见证候分型；运用因子分析的方法对UAP的常见证候要素进行归纳总结；运用QUEST决策树算法,探索证候要素和粘附分子P-选择素,VCAM-1的内在联系。
2.通过免疫组化、免疫蛋白印迹和荧光实时定量PCR的方法,模拟冠心病心绞痛缺血发作时的病理机制,对HCMEC进行缺糖缺氧和复糖复氧处理,观察黄芪多糖干预缺血再灌注损伤模型HCMEC下P-选择素、VCAM-1的蛋白表达和mRNA转录水平变化,以及P38和NF-Kb的磷酸化活性水平。
结果
1.UAP证候分型：运用Kohonen网络聚类方法,UAP证候聚为9个证型,按构成比排列依次为心血瘀阻(20.99%)、气虚血瘀夹痰(14.89%)、阳虚血瘀(11.83%)、心气亏虚(11.45%)、气阴两虚(10.69%)、痰浊壅滞(10.69%)、气郁(滞)化火(热)(9.16%)、痰热壅滞(6.49%)、心阳亏虚(3.82%)。
2.UAP证候要素：采用因子分析方法分析UAP患者临床症状,得到具有中医理论意义的7个公因子(证候要素),按构成比排列依次为血瘀(47.33%),气虚(38.55%)、痰浊(27.10%)、热蕴(20.61%)、气滞(16.03%)、阴虚(15.27%)、阳虚(14.89%)；57种组合型证候要素中,≥10例有6型,>10～≥5例有9型,>5～≥3例有11型,2例有10型,1例有21型,其中血瘀(15.85%)、气虚(12.83%)、气虚血瘀(7.17%)型最多。
3.UAP证候类型与粘附分子关系：各组证候类型的P-selectin、VCAM-1浓度之间有统计学差异(P<0.01), P-selectin浓度以气虚血瘀夹痰组<血瘀组<阳虚血瘀组<痰浊或兼化热组<气滞或兼化热组<痰浊组<气阴两虚组<气虚<阳虚；与气虚血瘀夹痰组比较,除血瘀组外的其他各组均有统计学差异(P<0.05,P<0.01),与气虚组比较,除气阴两虚、阳虚组外其他各组均有统计学差异(P<0.05, P<0.01)。VCAM-1浓度以气虚血瘀夹痰<痰浊或兼化热<血瘀组<气滞或兼化热组<阳虚血瘀<痰浊组<气阴两虚组<气虚<阳虚；与气虚血瘀夹痰组比较,除心血瘀阻、气郁(滞)化火(热)、痰热蕴结外的其他各组均有统计学差异(P<0.05,P<0.01),与气虚组比较,除心气亏虚、气阴两虚、痰浊阻滞外的其他各型均有统计学差异(P<0.05,P<0.01)。
UAP证候要素与粘附分子关系(QUEST算法)：气虚与低浓度P-selectin值有关,与VCAM-1的浓度关系不明显；瘀血与高浓度P-selectin值有关,与VCAM-1浓度有一定关系,但关系较复杂；痰浊与P-selectin的浓度关系不明显,与高浓度VCAM-1值有关；热蕴与一定范围较高浓度的VCAM-1有关,与P-selectin的浓度关系不明显；阳虚与低浓度P-selectin、VCAM-1值均有关；阴虚和气滞与P-selectin、VCAM-1的浓度关系不明显。即P-selectin在瘀血存在时呈高表达,气虚、阳虚时呈低表达；VCAM-1在瘀血、热蕴、痰浊存在时呈高表达,阳虚时呈低表达。
4.损伤模型粘附分子及P38和NF-κb基因转录水平和蛋白表达：模拟冠心病心绞痛缺血发作时的病理机制,对人心脏微血管内皮细胞(HCMEC)进行缺糖缺氧和复糖复氧处理后,P-selectin、VCAM-1蛋白表达和1nRNA转录水平比正常组明显增高(P<0.05,P<0.01),P-P38和其下游靶点ATF-2、NF-κb下游靶点iκb的mRNA基因转录水平比正常组明显增高(P<0.01)。
5.黄芪多糖干预损伤后粘附分子及P38和NF-κb基因转录水平和蛋白表达：HCMEC的P-selectin、VCAM-1蛋白表达和mRNA转录水平较模型组比较明显下调(P<0.05, P<0.01), P-P38、ATF-2、iκb的mRNA基因转录水平较模型组有显著下降(P<0.01),与NF-κb抑制剂PDTC和P38抑制剂SB203580比较无统计学差异(P>0.05)。
结论
1.UAP证候类型以心血瘀阻和气虚血瘀夹痰型最为多见。
2.UAP证候要素为血瘀、气虚、痰浊、热蕴、气滞、阴虚、阳虚；以组合型证候要素居多,组合规律复杂多样,其中血瘀、气虚、气虚血瘀型最多。
3. P-selectin、VCAM-1在虚实夹杂和实证时表达较高,以气虚血瘀夹痰证最高,在虚证时表达偏低,以阳气亏虚的浓度最低。QUEST算法提示,P-selectin的浓度直接反映瘀血的程度,间接反映痰浊的程度；VCAM-1的浓度直接反映痰浊程度,间接反映瘀血、热蕴程度；热蕴对增加P-selectin、VCAM-1浓度起促进作用；气滞对P-selectin、VCAM-1浓度的影响小于痰、瘀对二者的影响。
4.正常HCMEC中P38和NF-κb活性受到相对抑制,使P-selectin、VCAM-1处于低表达、低转录水平,损伤后P38和NF-κb活性明显增强,使P-selectin、VCAM-1表达和转录明显增高,加重细胞损伤。
5.黄芪多糖能下调HCMEC的P-selectin、VCAM-1表达及转录,具有浓度依赖性；对P38和NF-κb活性起到一定的抑制作用,抑制效果与PDTC和SB203580比较无差异；对P38通路和NF-κb通路的信号转导有共同抑制作用,通过抑制两通路的活性,使依靠这两条通路转录基因和表达蛋白的粘附分子(P-selectin、VCAM-1)水平被有效降低,阻断粘附分子介导的内皮细胞和白细胞粘附后,白细胞释放大量细胞毒性介质对内皮的损伤。
本研究UAP者以血瘀、气虚多见,血清中sP-selectin、sVCAM-1虚证时偏低表达,虚实夹杂和实证时较高表达；经缺氧再灌注损伤造模后,高度表达的P-selectin、VCAM-1经黄芪多糖干预后浓度明显下降,推测以益气为主的黄芪,兼有活血的功效,在UAP的治疗中起到了非常重要的作用。
Objective
To generalize syndrome patterns and syndrome factors in unstable angina pectoris coro-nary heart disease patients by statistical and data mining methods and study links between it, the adhesion molecule of P-selectin in serum and concentration variations of VCAM-1. Futherly capture more objective and implicit relations by unsupervised machinery data analy-sis.
With the help of ischemia-reperfusion model of human cardiac microvascular endothelial cell to imitate the damage of ischemia of angina pectoris onset on vascular endothelial cell and study the intervention effect of Astragalus Polysaccharide on adhesion molecule such as P-selectin and VCAM-1and its signal transduction mechanism of P38and NF-kb.
Method
1. Kohonen network clustering was adopted to analyze the symptoms of265unstable angina pectoris (UAP) cases and thus received the common syndrome pattern of UAP. Factor analysis was used to summarize and generalize the syndrome factors. At last, Decision Tree Algorithm was applied for detection of inner connections between syndrome factors, P-selectin and VCAM-1.
2. Human cardiac microvascular endothelial cell (HCMEC) was managed by ischemia-reperfusion to imitate the damage of ischemia of angina pectoris onset on vascular endothelial cell. Variations of protein expression of P-selectin and VCAM-1as well as transcription level of mRNA, phosphorylation of P38and NF-Kb in HCMEC in ischemia-reperfusion model intervened by Astragalus Polysaccharide with the help of immunohistochemistry, western botting and quantitative real time PCR assay.
Result
1. UAP syndrome pattern:According to Kohonen network clustering, the syndrome pattern of UAP were divided into9catigories as below:heart-blood stasis (20.99%), qi deficiency with bood stasis plus phlegm (14.89%), yang deficiency with blood stasis (11.83%), heart-qi deficiency (11.45%), qi and yin deficiency (10.69%), phlegm-turbid obstruction (10.69%), depressed qi transforming into heat (9.16%), phlegm-heat stagnation (6.49%), heart yang deficiency (3.82%)。
2. UAP syndrome factor:According to factor analysis, the analysis results of symptoms of UAP patients was received seven common factors (symptom factors) that were blood stasis (47.33%), qi dificiency (38.55%), phlegm turbid (27.10%), heat retention (20.61%) qi stagnation (16.03%), yin deficiency (15.27%) and yang deficiency (14.89%).Forthe57kinds of cyndrome pattern matches; more than ten cases had six factors; five to ten cases had nine factors; three to five cases had eleven factors; two cases had ten factors; one case had twenty-one factors. Among these mathes, bood stasis (15.85%), qi deficiency (12.83%) and qi deficiency with blood stasis (7.17%) were the most frequent patterns.
3. The relation between UAP syndrome pattern and adhesion molecules:There were significant differences between P-selectin and VCAM-1concentration of different syndrome patterns (P<0.01). The P-selectin level from lowest to highest in turn:qi deficiency with bood stasis plus phlegm, blood stasis, yang deficiency with blood stasis, phlegm-heat stagnation, depressed qi transforming into heat, phlegm-turbid obstruction, qi and yin deficiency and qi deficiency and yang deficiency. Except for blood stasis group, all other groups had statistical differentces in contrast to qi deficiency with bood stasis plus phlegm group (P<0.05or P<0.01). Besides qi and yin deficiency and yang deficiency group, all other groups showed significant differences in comparison to qi deficiency group. The VCAM-1level from lowest to highest in turn:qi deficiency with bood stasis plus phlegm, phlegm-heat stagnation, blood stasis, depressed qi transforming into heat, yang deficiency with blood stasis, phlegm-turbid obstruction, qi and yin deficiency, qi deficiency and yang deficiency (P<0.05, P<0.01) Except blood stasis, depressed qi transforming into heat and phlegm-heat stagnation group, all other groups had statistical differentces in contrast to qi deficiency with bood stasis plus phlegm group (P<0.05or P<0.01). Besides qi and yin deficiency, phlegm-turbid obstruction and ya deficiency group, all other groups showed significant differences in comparison to qi deficiency group (P＜0.05, P＜0.01)
The relation between UAP syndrome factor and adhesion molecules (QUEST algo-rithm):Qi deficiency is related to low P-selectin level rather than VCAM-1level; blood stasis is related to high P-selectin and VCAM-1level; phlegm turbid is linked to high VCAM-1; heat retention is linked to high VCAM-1concentration; yang deficiency is related to low P-selectin level; yin deficiency and qi stagnation had nothing to do with P-selectin and VCAM-1level. Thus, P-selectin had a high expression in blood stasis syndrome while had a low expression in yang deficiency and qi deficiency syndrome; VCAM-1expressed highly in blood stasis, heat retention and phlegm turbid syndrome pattern while expressed low in yang deficiency syndrome.
4. Protein expression and mRNA transcription level of adhesion molecules and P38、 NF-Kb by ischemia-reperfusion:It was observed that protein expression as well as mRNA transcription level of P-selectin and VCAM-1were higher than normal group (P＜0.05, P<0.01). While the mRNA transcription level of P-P38and its target ATF-2as well as NF-Kb and its target ixb were significantly elevated in contrast to normal group (P<0.01)
5. Protein expression and mRNA transcription level of adhesion molecules and P38、 NF-Kb after intervention by Astragalus Polysaccharide:Protein expression as well as mRNA transcription level of P-selectin and VCAM-1of model group were obviously down-regulated than control group (P＜0.05, P<0.01). While the mRNA transcription level of P-P38, ATF-2and kb mRNA dropped drastically than model group (P<0.01). However, in comparison to PDTC, the inhibitor of NF-Kb and to SB203580which is the inhibitor of P38, there was no statistical difference (P>0.05)
Conclusion
1. In UAP patients, heart-blood obstruction and qi deficiency with bood stasis plus phlegm sydrome were the most common ones.
2. The syndrome factors of UAP were blood stasis, qi dificiency, phlegm turbid, heat retention, qi stagnation, yin deficiency and yang deficiency and they were commonly observed in combinated forms. The rule of combination was complicated and blood stasis, qi deficiency and qi deficiency with blood stasis were the most popular ones.
3. P-selectin and VCAM-1had a high expression in intermingled deficiency and exces-sive syndrome and excessive syndromes, especially in qi deficiency with bood stasis plus phlegm syndrome. In additon, they had a low expression in deficiency syndromes and their expression were lowest in yang and qi deficiency synreome pattern. Thus it was speculated that the concentration of P-selectin reflected the degree of blood stasis directly while reflected the degree of phlegm-turbid indirectly. As for VCAM-1concentration, it mirrored phlegm-turbid directly while mirrored blood stasis and heat retention level indirectly. Heat retention promoted the density of P-selectin and VCAM-1and its effect was greater than the force of qi stagnation.
4. In HCMEC under normal cultivation circumstance, the activity of P38and NF-Kb were inhibited and P-selectin and VCAM-1were in low expression and transcription level. After treated by ischemia-reperfusion, activity of P38and NF-Kb in HCMEC enhanced sub-stantially. In the mean time, expression and transcription level of P-selectin and VCAM-1promoted significant, causing further damage cellular injury.
5. After intervened by Astragalus Polysaccharide, protein expression as well as mRNA transcription level of P-selectin and VCAM-1in HCMEC down-regulated obviously which saved as inhibtor of P38and NF-Kb with similar effects as PDTC and SB203580. Thus, it was speculated that Astragalus Polysaccharide was of impressive effects on signaling pathway of P38together with signal transduction of NF-Kb. Additionally, the concentration-dependent effect was achieved by declined the activity of pathways mentioned above leading to dropped level of related adhesion molecules as P-selectin and VCAM-1. Finally, the adhesion mole-cule mediated endothelial cell and white cell adhesion was therefore blocked and thus white cells were arrested from releasing cytotoxic mediators to damage the endothelial cells.
In the study of UAP patients, blood stasis and qi dificiency were the most common ones. P-selectin and VCAM-1had a high expression in intermingled deficiency and excessive syn-drome and excessive syndromes. In additon, they had a low expression in deficiency syndromes. After hypoxia reperfusion injury, the high expression of P-selectin, VCAM-1concentrations decreased significantly after intervention by astragalus polysaccharide, presumably astragalus have both supplementing qi and activating blood circulation, and plays a very important role in the treatment of UAP.
以统计学和数据挖掘方法,从冠心病不稳定性心绞痛患者临床信息中归纳证候类型和证候要素,并研究其与血清中粘附分子P-选择素,VCAM-1浓度变化的关系,从无监督的机器分析数据方法中,获得较客观的更深层次隐含关系。
通过对人心脏微血管内皮细胞(HCMEC)进行缺糖缺氧和复糖复氧造模,模拟心绞痛发作时缺血对血管内皮的损伤机制,研究黄芪多糖对内皮损伤时粘附分子(P-选择素,VCAM-1)表达的干预作用和对P38和NF-Kb通路的信号转导机制。
方法
1.运用Kohonen网络聚类方法,对265例不稳定性心绞痛(UAP)患者的临床症状聚类分析,获得不稳定性心绞痛(UAP)的临床常见证候分型；运用因子分析的方法对UAP的常见证候要素进行归纳总结；运用QUEST决策树算法,探索证候要素和粘附分子P-选择素,VCAM-1的内在联系。
2.通过免疫组化、免疫蛋白印迹和荧光实时定量PCR的方法,模拟冠心病心绞痛缺血发作时的病理机制,对HCMEC进行缺糖缺氧和复糖复氧处理,观察黄芪多糖干预缺血再灌注损伤模型HCMEC下P-选择素、VCAM-1的蛋白表达和mRNA转录水平变化,以及P38和NF-Kb的磷酸化活性水平。
结果
1.UAP证候分型：运用Kohonen网络聚类方法,UAP证候聚为9个证型,按构成比排列依次为心血瘀阻(20.99%)、气虚血瘀夹痰(14.89%)、阳虚血瘀(11.83%)、心气亏虚(11.45%)、气阴两虚(10.69%)、痰浊壅滞(10.69%)、气郁(滞)化火(热)(9.16%)、痰热壅滞(6.49%)、心阳亏虚(3.82%)。
2.UAP证候要素：采用因子分析方法分析UAP患者临床症状,得到具有中医理论意义的7个公因子(证候要素),按构成比排列依次为血瘀(47.33%),气虚(38.55%)、痰浊(27.10%)、热蕴(20.61%)、气滞(16.03%)、阴虚(15.27%)、阳虚(14.89%)；57种组合型证候要素中,≥10例有6型,>10～≥5例有9型,>5～≥3例有11型,2例有10型,1例有21型,其中血瘀(15.85%)、气虚(12.83%)、气虚血瘀(7.17%)型最多。
3.UAP证候类型与粘附分子关系：各组证候类型的P-selectin、VCAM-1浓度之间有统计学差异(P<0.01), P-selectin浓度以气虚血瘀夹痰组<血瘀组<阳虚血瘀组<痰浊或兼化热组<气滞或兼化热组<痰浊组<气阴两虚组<气虚<阳虚；与气虚血瘀夹痰组比较,除血瘀组外的其他各组均有统计学差异(P<0.05,P<0.01),与气虚组比较,除气阴两虚、阳虚组外其他各组均有统计学差异(P<0.05, P<0.01)。VCAM-1浓度以气虚血瘀夹痰<痰浊或兼化热<血瘀组<气滞或兼化热组<阳虚血瘀<痰浊组<气阴两虚组<气虚<阳虚；与气虚血瘀夹痰组比较,除心血瘀阻、气郁(滞)化火(热)、痰热蕴结外的其他各组均有统计学差异(P<0.05,P<0.01),与气虚组比较,除心气亏虚、气阴两虚、痰浊阻滞外的其他各型均有统计学差异(P<0.05,P<0.01)。
UAP证候要素与粘附分子关系(QUEST算法)：气虚与低浓度P-selectin值有关,与VCAM-1的浓度关系不明显；瘀血与高浓度P-selectin值有关,与VCAM-1浓度有一定关系,但关系较复杂；痰浊与P-selectin的浓度关系不明显,与高浓度VCAM-1值有关；热蕴与一定范围较高浓度的VCAM-1有关,与P-selectin的浓度关系不明显；阳虚与低浓度P-selectin、VCAM-1值均有关；阴虚和气滞与P-selectin、VCAM-1的浓度关系不明显。即P-selectin在瘀血存在时呈高表达,气虚、阳虚时呈低表达；VCAM-1在瘀血、热蕴、痰浊存在时呈高表达,阳虚时呈低表达。
4.损伤模型粘附分子及P38和NF-κb基因转录水平和蛋白表达：模拟冠心病心绞痛缺血发作时的病理机制,对人心脏微血管内皮细胞(HCMEC)进行缺糖缺氧和复糖复氧处理后,P-selectin、VCAM-1蛋白表达和1nRNA转录水平比正常组明显增高(P<0.05,P<0.01),P-P38和其下游靶点ATF-2、NF-κb下游靶点iκb的mRNA基因转录水平比正常组明显增高(P<0.01)。
5.黄芪多糖干预损伤后粘附分子及P38和NF-κb基因转录水平和蛋白表达：HCMEC的P-selectin、VCAM-1蛋白表达和mRNA转录水平较模型组比较明显下调(P<0.05, P<0.01), P-P38、ATF-2、iκb的mRNA基因转录水平较模型组有显著下降(P<0.01),与NF-κb抑制剂PDTC和P38抑制剂SB203580比较无统计学差异(P>0.05)。
结论
1.UAP证候类型以心血瘀阻和气虚血瘀夹痰型最为多见。
2.UAP证候要素为血瘀、气虚、痰浊、热蕴、气滞、阴虚、阳虚；以组合型证候要素居多,组合规律复杂多样,其中血瘀、气虚、气虚血瘀型最多。
3. P-selectin、VCAM-1在虚实夹杂和实证时表达较高,以气虚血瘀夹痰证最高,在虚证时表达偏低,以阳气亏虚的浓度最低。QUEST算法提示,P-selectin的浓度直接反映瘀血的程度,间接反映痰浊的程度；VCAM-1的浓度直接反映痰浊程度,间接反映瘀血、热蕴程度；热蕴对增加P-selectin、VCAM-1浓度起促进作用；气滞对P-selectin、VCAM-1浓度的影响小于痰、瘀对二者的影响。
4.正常HCMEC中P38和NF-κb活性受到相对抑制,使P-selectin、VCAM-1处于低表达、低转录水平,损伤后P38和NF-κb活性明显增强,使P-selectin、VCAM-1表达和转录明显增高,加重细胞损伤。
5.黄芪多糖能下调HCMEC的P-selectin、VCAM-1表达及转录,具有浓度依赖性；对P38和NF-κb活性起到一定的抑制作用,抑制效果与PDTC和SB203580比较无差异；对P38通路和NF-κb通路的信号转导有共同抑制作用,通过抑制两通路的活性,使依靠这两条通路转录基因和表达蛋白的粘附分子(P-selectin、VCAM-1)水平被有效降低,阻断粘附分子介导的内皮细胞和白细胞粘附后,白细胞释放大量细胞毒性介质对内皮的损伤。
本研究UAP者以血瘀、气虚多见,血清中sP-selectin、sVCAM-1虚证时偏低表达,虚实夹杂和实证时较高表达；经缺氧再灌注损伤造模后,高度表达的P-selectin、VCAM-1经黄芪多糖干预后浓度明显下降,推测以益气为主的黄芪,兼有活血的功效,在UAP的治疗中起到了非常重要的作用。
Objective
To generalize syndrome patterns and syndrome factors in unstable angina pectoris coro-nary heart disease patients by statistical and data mining methods and study links between it, the adhesion molecule of P-selectin in serum and concentration variations of VCAM-1. Futherly capture more objective and implicit relations by unsupervised machinery data analy-sis.
With the help of ischemia-reperfusion model of human cardiac microvascular endothelial cell to imitate the damage of ischemia of angina pectoris onset on vascular endothelial cell and study the intervention effect of Astragalus Polysaccharide on adhesion molecule such as P-selectin and VCAM-1and its signal transduction mechanism of P38and NF-kb.
Method
1. Kohonen network clustering was adopted to analyze the symptoms of265unstable angina pectoris (UAP) cases and thus received the common syndrome pattern of UAP. Factor analysis was used to summarize and generalize the syndrome factors. At last, Decision Tree Algorithm was applied for detection of inner connections between syndrome factors, P-selectin and VCAM-1.
2. Human cardiac microvascular endothelial cell (HCMEC) was managed by ischemia-reperfusion to imitate the damage of ischemia of angina pectoris onset on vascular endothelial cell. Variations of protein expression of P-selectin and VCAM-1as well as transcription level of mRNA, phosphorylation of P38and NF-Kb in HCMEC in ischemia-reperfusion model intervened by Astragalus Polysaccharide with the help of immunohistochemistry, western botting and quantitative real time PCR assay.
Result
1. UAP syndrome pattern:According to Kohonen network clustering, the syndrome pattern of UAP were divided into9catigories as below:heart-blood stasis (20.99%), qi deficiency with bood stasis plus phlegm (14.89%), yang deficiency with blood stasis (11.83%), heart-qi deficiency (11.45%), qi and yin deficiency (10.69%), phlegm-turbid obstruction (10.69%), depressed qi transforming into heat (9.16%), phlegm-heat stagnation (6.49%), heart yang deficiency (3.82%)。
2. UAP syndrome factor:According to factor analysis, the analysis results of symptoms of UAP patients was received seven common factors (symptom factors) that were blood stasis (47.33%), qi dificiency (38.55%), phlegm turbid (27.10%), heat retention (20.61%) qi stagnation (16.03%), yin deficiency (15.27%) and yang deficiency (14.89%).Forthe57kinds of cyndrome pattern matches; more than ten cases had six factors; five to ten cases had nine factors; three to five cases had eleven factors; two cases had ten factors; one case had twenty-one factors. Among these mathes, bood stasis (15.85%), qi deficiency (12.83%) and qi deficiency with blood stasis (7.17%) were the most frequent patterns.
3. The relation between UAP syndrome pattern and adhesion molecules:There were significant differences between P-selectin and VCAM-1concentration of different syndrome patterns (P<0.01). The P-selectin level from lowest to highest in turn:qi deficiency with bood stasis plus phlegm, blood stasis, yang deficiency with blood stasis, phlegm-heat stagnation, depressed qi transforming into heat, phlegm-turbid obstruction, qi and yin deficiency and qi deficiency and yang deficiency. Except for blood stasis group, all other groups had statistical differentces in contrast to qi deficiency with bood stasis plus phlegm group (P<0.05or P<0.01). Besides qi and yin deficiency and yang deficiency group, all other groups showed significant differences in comparison to qi deficiency group. The VCAM-1level from lowest to highest in turn:qi deficiency with bood stasis plus phlegm, phlegm-heat stagnation, blood stasis, depressed qi transforming into heat, yang deficiency with blood stasis, phlegm-turbid obstruction, qi and yin deficiency, qi deficiency and yang deficiency (P<0.05, P<0.01) Except blood stasis, depressed qi transforming into heat and phlegm-heat stagnation group, all other groups had statistical differentces in contrast to qi deficiency with bood stasis plus phlegm group (P<0.05or P<0.01). Besides qi and yin deficiency, phlegm-turbid obstruction and ya deficiency group, all other groups showed significant differences in comparison to qi deficiency group (P＜0.05, P＜0.01)
The relation between UAP syndrome factor and adhesion molecules (QUEST algo-rithm):Qi deficiency is related to low P-selectin level rather than VCAM-1level; blood stasis is related to high P-selectin and VCAM-1level; phlegm turbid is linked to high VCAM-1; heat retention is linked to high VCAM-1concentration; yang deficiency is related to low P-selectin level; yin deficiency and qi stagnation had nothing to do with P-selectin and VCAM-1level. Thus, P-selectin had a high expression in blood stasis syndrome while had a low expression in yang deficiency and qi deficiency syndrome; VCAM-1expressed highly in blood stasis, heat retention and phlegm turbid syndrome pattern while expressed low in yang deficiency syndrome.
4. Protein expression and mRNA transcription level of adhesion molecules and P38、 NF-Kb by ischemia-reperfusion:It was observed that protein expression as well as mRNA transcription level of P-selectin and VCAM-1were higher than normal group (P＜0.05, P<0.01). While the mRNA transcription level of P-P38and its target ATF-2as well as NF-Kb and its target ixb were significantly elevated in contrast to normal group (P<0.01)
5. Protein expression and mRNA transcription level of adhesion molecules and P38、 NF-Kb after intervention by Astragalus Polysaccharide:Protein expression as well as mRNA transcription level of P-selectin and VCAM-1of model group were obviously down-regulated than control group (P＜0.05, P<0.01). While the mRNA transcription level of P-P38, ATF-2and kb mRNA dropped drastically than model group (P<0.01). However, in comparison to PDTC, the inhibitor of NF-Kb and to SB203580which is the inhibitor of P38, there was no statistical difference (P>0.05)
Conclusion
1. In UAP patients, heart-blood obstruction and qi deficiency with bood stasis plus phlegm sydrome were the most common ones.
2. The syndrome factors of UAP were blood stasis, qi dificiency, phlegm turbid, heat retention, qi stagnation, yin deficiency and yang deficiency and they were commonly observed in combinated forms. The rule of combination was complicated and blood stasis, qi deficiency and qi deficiency with blood stasis were the most popular ones.
3. P-selectin and VCAM-1had a high expression in intermingled deficiency and exces-sive syndrome and excessive syndromes, especially in qi deficiency with bood stasis plus phlegm syndrome. In additon, they had a low expression in deficiency syndromes and their expression were lowest in yang and qi deficiency synreome pattern. Thus it was speculated that the concentration of P-selectin reflected the degree of blood stasis directly while reflected the degree of phlegm-turbid indirectly. As for VCAM-1concentration, it mirrored phlegm-turbid directly while mirrored blood stasis and heat retention level indirectly. Heat retention promoted the density of P-selectin and VCAM-1and its effect was greater than the force of qi stagnation.
4. In HCMEC under normal cultivation circumstance, the activity of P38and NF-Kb were inhibited and P-selectin and VCAM-1were in low expression and transcription level. After treated by ischemia-reperfusion, activity of P38and NF-Kb in HCMEC enhanced sub-stantially. In the mean time, expression and transcription level of P-selectin and VCAM-1promoted significant, causing further damage cellular injury.
5. After intervened by Astragalus Polysaccharide, protein expression as well as mRNA transcription level of P-selectin and VCAM-1in HCMEC down-regulated obviously which saved as inhibtor of P38and NF-Kb with similar effects as PDTC and SB203580. Thus, it was speculated that Astragalus Polysaccharide was of impressive effects on signaling pathway of P38together with signal transduction of NF-Kb. Additionally, the concentration-dependent effect was achieved by declined the activity of pathways mentioned above leading to dropped level of related adhesion molecules as P-selectin and VCAM-1. Finally, the adhesion mole-cule mediated endothelial cell and white cell adhesion was therefore blocked and thus white cells were arrested from releasing cytotoxic mediators to damage the endothelial cells.
In the study of UAP patients, blood stasis and qi dificiency were the most common ones. P-selectin and VCAM-1had a high expression in intermingled deficiency and excessive syn-drome and excessive syndromes. In additon, they had a low expression in deficiency syndromes. After hypoxia reperfusion injury, the high expression of P-selectin, VCAM-1concentrations decreased significantly after intervention by astragalus polysaccharide, presumably astragalus have both supplementing qi and activating blood circulation, and plays a very important role in the treatment of UAP.
引文
[1]黄文林,朱孝峰主编.信号转导[M].北京：人民卫生出版社,2005,234-257.
[2]Atherosclerosis as an Inflammatory Disease. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis-an inflammation disease[J]. Curr Pharm Des,201229:115-126.
[3]李艳,黄从新.重要炎性因子在冠心病病理过程中的作用[J].微循环杂志,2004,14(1)：47-49.
[4]李守贵.ACS患者血清sICAM-1、sVCAM-1、可溶性P选择素的水平变化及意义.山东医药,2009,49(17)：84.
[5]暴清波,贾永平,吕吉元,等.IMA、P选择素和hs-CRP联合检测对早期诊断不稳定性心绞痛的作用研究[J].中西医结合心脑血管病杂志.2010,8(6)：657-659.
[6]孙丽,郭晓玲.冠心病患者血清E-选择素和Ox-LDL的测定及意义[J].包头医学院学报,2008,24(6)：580-581.
[7]韩学杰.沈绍功教授从痰论治冠心病经验[J].中国中医急症,2004,13(1)：31.
[8]Carter YM, Thomas R, Bargatze R, et al. Intracoronary E-/L-selectin blockade reduces neutrophil infiltration in heart transplantation[J]. Ann Thorac Surg,2002,74(6):2064-2070.
[9]Duda M, Czarnowska E, Kurzelewski M, et al. Ischemic preconditioning prevents endothelial dysfunction, P-selectin expression, and neutrophil adhesion by preventing en-dothelin and 02-generation in the post-ischemic guinea-pig heart. [J]. J Physiol Pharmacol, 2006,57(4):553-69.
[10]Hamaad A, Sosin MD, Blann AD, et al. Markers of Thrombosis and Hemostasis in Acute Coronary Syndromes:Relationship to Increased Heart Rate and Reduced Heart-Rate Varia-bility[J]. Clin Cardiol,2009,32(4):204-209.
[11]Golias C, Tsoutsi E, Matziridis A, et al. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. [J]. In Vivo,2007,21(5): 757-69.
[12]Ley K. The role of selectins in inflammation and disease[J]. Trends Mol Med,2003, 9(6):263-8.
[13]林琦,覃家锦,冯旭.P-选择素与体外循环关系的研究进展[J].微创医学,2009,4(2)：165-167.
[14]Alcaide P, Auerbach S, Luscinskas FW. Neutrophil Recruitment under Shear Flow: It's All about Endothelial Cell Rings and Gaps[J]. Microcirculation,2008,16(1):43-57.
[15]Shebuski RJ, Kilgore KS. Role of Inflammatory Mediators in Thrombogenesis [J]. J. Pharmaeol Exp Ther,2002,300(3):729-735.
[16]Libby P. Changing concepts of atherogenesis[J]. J Intern Med,2000,247(3):349-58.
[17]Dewberry R, Holden H, Crossman D, et al. Interleukin-Ireceptor antagonist expression in human endothelial eell and atherosclerosis [J]. Arterioscler Thromb Vase Biol,2000、20: 2394.
[18]Jia G, Aggarwal A, Tyndall SH, et al. Tumor necrosis factor-α regulates p27 kip expression and apoptosis in smooth muscle cells of human carotid plaques via forkhead tran-scription factor O1 [J]. Exp. Mol. Pathol,2001,90(1):1-8.
[19]Dietrich T, Hucko T, Schneemann C, et al. cal delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells[J]. Atherosclerosis,2011,220(2):329-36.
[20]Blann AD, Draper Z. Platelet activation as a marker of heart attack. [J]. Clin. Chim Acta,2011,412(11-12):841-2.
[21]Koyama H, Maeno T, Fukumoto S, et al. Platelet P-Selectin Expression Is Associated With Atherosclerotic Wall Thickness in Carotid Artery in Humans Circulation[J].2003,108: 524.
[22]Haverslag R, Pasterkamp G, Hoefer IE. Targeting adhesion molecules in cardiovascular disorders[J].Cardiovascular & hematological disorders drug targets,2008,8(4):252-60.
[23]Chen F, Castranova V, Shi X.New insights into the role of nuclear factor-kappaB in cell growth regulation[J]. Am J Pathol,2001,159(2):387-397.
[24]Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human vronchial epithelial cells by a NFkb ERK-dependent mechanism[J]. Eur J Pharmacol, 2008,582:145-153.
[25]Christopher P, Baines and Jeffery D, Molkentin. STRESS signaling pathways that modulate cardiac myocyte apoptosis[J]. J Mol Cell Cardiol,2005,38(1):47-62.
[26]刘杰,阚丹.Ⅰκκ/ⅠκB/NF-κb信号通路阻断及临床应用.实用医学杂志,2008,24(23)：4147-4149.
[27]Wang T, Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress res-ponses. [J]. Int. Immunopharmacol,2002,2(11):1509-20.
[28]Chen YH, Lin SJ, Chen JW, et al. Magnolol attenuates VC AM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits[J]. Br J Pharmacol,2002,135(1):37-47.
[29]Squadrito F, Deodato B, Squadrito G, et al. Gene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury[J]. Lab Invest,2003,83(8): 1097-1104.
[30]Yeh CH, Lin YM, Wu YC, et al. Inhibition of NF-kappa B activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proin-flammatory gene up-regulation and matrix metalloproteinase expression[J]. J Cardiovasc Pharmacol,2005,45(4):301-9.
[31]Temming K, Lacombe M, van der Hoeven P, et al. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells:development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(Ⅱ)-based drug linker technolo-gy[J]. Bioconjug Chem,2006,17(5):1246-1255.
[32]Frenette PS, Denis CV, Weiss L, et al. p-Selectin Glycoprotein Ligand 1(PSGL-1)Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vi-vo[J]. J. Exp. Med,2000,191:1413-1422.
[33]Carter AM, Anagnostopoulou K, Mansfield MW, et al. Soluble p-selectin levels, P-selectin polymorphisms and cardiovascular disease[J]. J Thromb Haemost,2003,1(8): 1718-1723.
[34]Barbaux SC, Blankenberg S, Rupprecht HJ, et al. Association between P selectin gene polymorphisms and soluble p-selectin levels and their relation to coronary artery disease[J]. Arterioscler Thromb Vase Biol,2001,21(10):1668-1673.
[35]Antoniades C, Bakogiannis C, Tousoulis D, et al. Platelet activation in atherogenesis associated with low-grade inflammation[J]. Inflamm Allergy Drug Targets,2010,9(5): 334-45.
[36]陈宇杰,陆信武.P-选择素与动脉粥样硬化形成[J].国外医学,生理病理科学与临床分册,2002,22(4)：323-325.
[37]Blake GJ, Ridker PM. Novel ciinical markers of vascular wall inflammation[J]. Circ Res,2001,89(9):763-771.
[38]Dong ZM, Brown AA, Wagner DD. Prominent role of p-selectin in the development of advance atherosclerosis in apoE-deficient mice[J]. Circulation,2000,101:2290-2295.
[39]Russo HM, Wickenheiser KJ, Luo W, et al. P-selectin glycoprotein ligand-1 regulates adhesive properties of the endothelium and leukocyte trafficking into adipose tis-sue[J]. Circ. Res,2010,107(3):388-97.
[40]Phillips JW, Barringhaus KG, Sanders JM, et al. Single Injection of p-Selectin or p-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Blocks Neointima Formation After Arterial Injury in Apolipoprotein E-Deficient Mice[J]. Circulation,2003,107(17): 2244-2249.
[41]Kabbani SS, Watkins MW, Holoch PA, et al. Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of an-ti-thrombotic therapy [J]. J Thromb ThrombolysiS,2001,12(2):171-176.
[42]Atalar E, hytemir K, Haznedaroglu I, et al. Increased plasma levels of soluble selectins in patients with unstable angina[J]. Int J Cardiol,2001,78(1):69-73.
[43]Kayikcioglu M, Can L, Mete-Erdem N, et al. Soluble p-selectin and the Success of thrombolysis in acute myocardial infarction[J]. Int J Cardiol,2001,79(2-3):223-229.
[44]Wang J, Zhang S, Jin Y, et al. Elevated levels of plat el et-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome[J]. Int. J. Cardiol, 2007,115(3):361-5.
[45]Zhang SZ, Jin YP, Qin GM, et al. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes[J]. Clin Cardiol,2007,30(1):26-31.
[46]Merten M, Thiagarajan P. p-selectin expression on platelets determines size and stability of platelet aggregates [J]. Circulation,2000,102(16):1931-1936.
[47]Burger PC and Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion devel-opment[J]. Blood,2003,101(7):2661-2666.
[48]于涛,曹洪欣.胸痹(冠心病)证候演变规律的临床研究[J].中医药信息,2004,21(3)：44.
[49]马晓昌,尹太英,陈可冀,等.冠心病中其分型冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(4)：254.
[50]Daniel M, Jr. DVM, Diana Farris LVT, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis[J]. J Surg Res,2002,108(2):212-221.
[51]Rossi B, Constantin G. Anti-selectin therapy for the treatment of inflammatory diseas-es[J]. Inflamm Allergy Drug Targets,2008,7(2):85-93.
[52]Blann A D, McCollum C N, Lip G Y. Relationship between plasma marker of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals[J]. Blood Coagulation & Fibrinolysis,2002,13:513.
[53]Kerner T, Ahlers O, Reschreiter H, et al. Adhesion molecules in different treatments of acute myocardial infarction[J]. Crit Care,2001,5(3):145-50.
[54]Sukhotnik I, Coran AG, Greenblatt R, et al. Effect of 100% oxygen on E-selectin expression, recruitment of neutrophils and enterocyte apoptosis following intestinal ische-mia-reperfusion in a rat[J]. Pediatr. Surg. Int,2008,24(1):29-35.
[55]Zarbock A, Ley K, McEver RP, et al. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow[J]. Blood,2011, 118(26):6743-51.
[56]Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease[J]. J Cardiol,2009,53(3):317-33.
[57]韦叶生,李艳,张平安,等.E-选择素A561C基因多态性与老年人不稳定心绞痛的相关性研究[J],中国老年学杂志,2003,23(10)：651-653.
[58]Zheng F, Chevalier J A, Zhang L Q, et al. An Hphl polymorphism in the E-selectin gene is associated with premature coronary artery disease[J]. Clin Genet,2001,59:58.
[59]Kavsak PA, Ko DT, Newman AM, et al. Upstream markers provide for early iden-tification of patients at high risk for myocardial necrosis and adverse out-comes[J]. Clin. Chim. Acta,2008,387(1-2):133-8.
[60]杨立森,林媛豪,石学宁,等.可溶性E选择素对冠心病心绞痛的诊断意义[J].临床心血管病杂志,2003,19(5)：272-274.
[61]Nusca A, Melfi R, Di Sciascio G. Percutaneous coronary interventions and statins therapy. [J]. Therapeutic advances in cardiovascular disease,2008,2(2):101-7.
[62]Lee JK, Kim JK, Park SH, et al. Lactosylceramide Mediates the Expression of Adhesion Molecules in TNF-a and IFNy-stimulated Primary Cultured Astrocytes[J]. Korean J. Physiol. Pharmacol,2011,15(5):251-8.
[63]Pietruczuk M, Pietruczuk A, Pancewicz S, et al. ICAM-1:structure, biological role and clinical significance[J]. Pol. Merkur. Lekarski,2004,17(101):507-11.
[64]金伯泉.细胞和分子免疫学(第二版)[M].北京：科学出版社,2003：34-386.
[65]Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease[J]. J Cardio,2009,53 (3):317-33.
[66]Wittchen ES. Endothelial signaling in paracellular and transcellular leukocyte transmi-gration[J]. Front. Biosci,2009,14:2522-45.
[67]Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human athe-rosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transen-dothelial migration[J]. Circ. Res.2011,108(3):335-43.
[68]Stephanie A, Camacho, William R, et al. A key rote for ICAM-1 in generating effeetor cells mediating inflammatory responses[J]. Nature Immunology,2001,2:523-529.
[69]Lawson C, Wolf S. ICAM-1 signaling in endothelial cells[J]. Pharmacol Rep,2009, 61(1):22-32.
[70]Rohlena J, Volger OL, van Buul JD, et al, Endothelial CD81 is a marker of early human atherosclerotic plaques and facilitates monocyte adhesion[J]. Cardiovasc. Res,2008,81(1): 187-96.
[71]Paessens LC, Singh SK, Fernandes RJ, et al. Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) provide co-stimulation in posi-tive selection along with survival of selected thymocytes[J]. Mol. Immunol,2008,45(1): 42-8.
[72]Nachtigal P, Kopecky M, Solichova D, et al. The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis[J]. J. Pharm. Pharmacol,2005,57(2):197-203.
[73]Combe C, Burton CJ, Dufourco P, et al. Hypoxia induces intercellular adhesion molecule-lon cultured human tubular cells[J]. Kidney Int,1997,51(6):1703-1709.
[74]Yamanashi Y, Mori M, Terajima K, et al. A transient inflammatory reaction in the lung after experimental hemorrhagic shock and resuscitation with a hemoglobin-vesicles solution compared with rat RBC transfusion[J]. ASAIO J,2009,55(5):478-83.
[75]Behnam SM, Behnam SE, Koo JY, et al. TNF-alpha inhibitors and congestive heart failure[J]. Skinmed,2005,4(6):363-8.
[76]Wang Y, Zhou Y, Meng L, et al. Inflammatory Mediators in Chinese Patients With Congestive Heart Failure[J]. J Clin Pharmacol,2009,49(5):591-9.
[77]罗成基,裴雪涛主编.造血微环境[M].北京：世界医药出版社,2001,1-50.
[78]司英健,张曦,陈幸华,等.VCAM-1和EGFP双基因共表达重组腺病毒的构建[J].重庆医学,2007,36(17)：1699-1703.
[79]Vcerans C, Van Hennik PB, vander Schoot CE. Homing of human hematopoiefic stem and progenitor cells:new insights, new challenges[J]. Hematother Stem Cell Res,2001, 10(6),725-738.
[80]Lapidot T, Dar A, Kollet O. How do stem cells find their way home[J]. Blood,2005, 106(6),1901-1910.
[81]张丽慧,魏尔清.ICAM-1、VCAM-1在脑缺血损伤炎症机制中的作用及调控[J].中国药理学通报,2005,21(11)：1281-1282.
[82]洪永敦,朱会英,陈宇鹏,等.冠心病痰瘀证候与E选择素G98T及S128R基因多态性的关系研究[J].广州中医药大学学报,2009,26(1),1-4.
[83]骆丽娟.冠心病证型与P-选择素、TXB2及6-Keto-PGF1α含量变化关系的研究[J].上海中医药杂志,2002,7,13-14.
[84]林桂永,王子健.冠心病血瘀证气血辨证与内皮细胞损伤的关系[J].中西医结合心脑血管病杂志,2005,3(10),856-858.
[85]柏正平,谭光波,卜献春,等.冠心病中医辨证分型与细胞黏附分子的关系[J].中西医结合心脑血管病杂志,2006,4(2),108-109.
[86]王锡煌,王挹青.血管生成素1通过NF-kB传导通路影响内皮祖细胞炎症反应中黏附分子的表达[J].中国动脉硬化杂志,2011,3：140-141.
[87]庄梅,方颖,吴立荣,等.地塞米松对大鼠缺血再灌注心肌细胞凋亡及HSP72、 NF-kB表达的影响[J].中国老年学杂志.2008,15：1467-1469.
[88]杨慎先,万大国,杜诗兵.瑞舒伐他汀对急性心肌梗死大鼠NF-kB和IL-6表达的影响[J].心脏杂志,2011,04：151-142.
[89]潘金生,刘应才,陈辉,等.阿托伐他汀钙对扩张型心肌病患者促炎性细胞因子表达和NF-KB/p65活化的影响[J].中国心血管杂志,2007.2：114-117.
[90]姜希娟,杜云,苏金玲,等.心脑血脉宁对家兔易损斑块模型血脂NF-kB和ICAM-1 mRNA表达的影响[J].辽宁中医杂志,2008,5：783-785.
[91]杨萍,周玉平.缺血再灌注心肌EPOR的表达调控及丹参酮ⅡA的干预作用[J].辽宁中医杂志,2012,1：70-72.
[92]尹梅,高海青,李保应.通心络对糖尿病大鼠心肌RAGE、NF-kB的影响[J].山东大学学报(医学版),2011,8：68-72.
[93]贾钰华,周玉平,陈育尧,等.定心方对大鼠缺血及再灌注心律失常的保护作用及对核因子κB活化的影响[J].中医杂志,2007,4：35-39.
[94]李向东,肖骅,覃数,等.辛伐他汀调节p38和CARP与改善心肌重塑的关系[J].中国药学杂志,2009,11：100-102.
[95]郑晓丹,严世芸,秦仲君.通心脉方对大鼠心肌缺血再灌注损伤AKt及p38αMAPK蛋白表达的影响[J].中医研究.2011.6：47-49.
[96]尹慧秋,张继东,林海青,等.舒脉胶囊改善心肌梗死大鼠左室重构与心功能的研究[J].山东中医药大学学报,2008,2：790-791.
[97]Han J, Kamber M. Data Ming. Concepts and Techniques[J]. Morgan Kaufmann Publishers,2000,5-14.
[98]吴凤娟,刁永峰.浅谈数据挖掘技术[J].乐山师范学院学报,2004,19(12)：96.
[99]薛薇,陈欢歌.Clementine数据挖掘方法及应用[M].电子工业出版社.北京.2010：120-180.
[100]崔雷.医学数据挖掘[M].高等教育出版社,北京,2006：56-69.
[101]薛薇,陈欢歌.Clementine数据挖掘方法及应用[M].电子工业出版社.北京.2010：271-301.
[102]刘仁权.SPSS统计软件[M].中国中医药出版社.北京：163-170.
[103]周晓宏,郭文静.探索性因子分析与验证性因子分析异同比较[J].科技和产业.2008.8(9)：69-71.
[104]张家放.医用多元统计方法[M].武汉：华中科技大学出版社,2002：323-338.
[105]赵铁牛,王泓午,刘桂芬.验证性因子分析及应用[J].中国卫生统计.2010,27(6)：608-609.
[106]宋毅,裴建,刘志丹,等.针刺干预缺血性中风病证候动态化及相关研究[J].中西医结合学报,2009,4：334-341.
[107]李晓宇.基于支撑向量机的中医舌色苔色识别算法研究[J].北京生物医学工程,2006,25(1)：43-46.
[108]瞿海斌,毛利锋,王阶.基于决策树的血瘀证诊断规则自动归纳方法[J].中国生物医学工程学报,2005,24(6)：709-711,727.
[109]徐蕾,贺佳,孟虹.基于信息熵的决策树在慢性胃炎中医辨证中的应用[J].第二军医大学学报,2004,25(9)：1009-1012.
[110]林维鉴.BP网络用于中医痹证证候分类[J].福建中医学院学报,1997,7(4)：41-43.
[111]胡随瑜,唐风英,喻长远,等.前馈反向传播网络在抑郁症中医证型分类中的初步研究[J].中医杂志,2004,45(7)：532-533.
[112]杜文斌.基于神经网络的冠心病证候诊断标准与药效评价模型研究[D].沈阳：辽宁中医学院,2004：4-5.
[113]张明雪,曹洪欣,常艳鹏,等.论“寒邪”在冠心病发病中的作用[J].中医药学报.2009,3：710-715.
[114]唐启盛,曲淼,包祖晓,等.抑郁症中医证候的贝叶斯网络研究[J].中医杂志,2008,49(11)：1013-1015.
[115]宓余强,伍喜良,曹武奎,等.72例慢性乙型重型肝炎症状与舌脉象聚类分析[J].传染病信息,2010,5：276-278.
[116]王阶,何庆勇,基于聚类分析和对应分析的稳定型心绞痛证候要素组合规律的研究[J].中西医结合学报.2008,7：690-694.
[117]陈建设,陈文垲.胃炎(胃脘痛)的证候聚类分析[J].辽宁中医杂志.2007,34(3)：292-293.
[118]王嘉麟,郭蓉娟,张允岭,等.基于因子分析的高血压病证候要素研究[J].天津中医药,2010,5：434-436.
[119]龚燕冰,罗增刚,高思华,等.运用因子分析方法探索2型糖尿病证候要素及其靶位特征[J].中医杂志,2011,52(13)：1102-1103.
[120]邹蔚萌,崔方圆,龙子弋,等.基于数据挖掘的缺血性中风火热证变化特征分析[J].辽宁中医杂志,2011,38(6)：1042-1044.
[121]陈明,杨慧芳,余蕾.基于关联规则的肝硬变辨证数据挖掘研究[J].河南中医,2009,29(3)：258-260.
[122]黄小波,李宗信,陈文强,等.慢性疲劳综合征气虚与血虚病机关系的定量分析.中国中医药科技,2007,14(1)：3-5.
[123]王伽伯,赵海平,肖小河,等.基于“有故无殒”思想和因子分析的大黄量-效(毒)关系研究[C].2010年中国药学大会暨第十届中国药师周论文集,2010,11：1-10.
[124]李续娥,张敏,李小梅,等.归胃经寒性中药对胃热证大鼠全身及胃机能影响的因子分析模型[J].生物数学学报,2008,4：25-27.
[125]何前锋,周雪忠,周忠眉,等.基于中药功效的聚类分析[J],中国中医药信息杂志,2004,11(6)：561-562.
[126]孙燕,臧佳新,任廷革.基于数据挖掘技术的医案整理方法探讨[J].中国中医药信息杂志,2006,13(11)：106-107.
[127]谭勇,吕爱平,车念聪,等.数据挖掘在中医学术流派研究中的应用[J].时珍国医国药,2007,18(12)：2990-2991.
[128]朱建贵,田琳,李平,等.基于信息和数据挖掘技术的名老中医临床诊疗经验研究思路[J].世界科学技术-中医药现代化,2005,7(1)：98-105.
[129]张灼,陈立新,宋崇顺,等.黄芪多糖对大鼠心肌缺血-再灌注损伤后的保护作用[J].中国中医药信息杂志,2007,14(2)：33-34.
[130]朱海燕,陈立新,朱陵群.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子-KB表达的影响[J].辽宁中医杂志,2008,35(1)：7-9.
[131]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[132]张灼,陈立新,宋崇顺,等.黄芪多糖对大鼠心肌缺血-再灌注损伤后的保护作用[J].中国中医药信息杂志,2007,14(2)：33-34.
[133]朱海燕,陈立新,朱陵群.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子-κB表达的影响[J].辽宁中医杂志,2008,35(1)：7-9.
[134]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[135]吴勇,欧阳静萍,涂淑珍,等.黄芪多糖对动脉粥样硬化内皮细胞损伤的影响[J].湖北中医学院学报,2002,4(1)：21.
[136]凌洪锋,苏丹,曹洋.黄芪多糖抗氧化作用研究[J].医学理论与实践,2005,18(8)：872-873.
[137]解慧梅,穆祥,胡格.黄芪多糖对大鼠肠黏膜微血管内皮细胞分泌NO的影响[J].北京农学院学报,2005,20(4)：58-61.
[138]Nathant C. Regulation of biosynthesis of nitric oxide[J]. Biol Chem,1994,269: 13725-13728.
[139]赵红卫,李晓玉.NO与免疫调节[J].上海免疫学杂志,1996,4(6)：373-376.
[140]魏毅,刘婷婷,林婷婷,等.黄芪多糖及其与白芍总苷协同对兔血小板聚集功能的影响魏[J].中国临床药理学与治疗学,2005,10(8)：932-934.
[141]许艳,高佩畸,梁庆成,等.黄芪多糖对脑血栓的疗效试验研究[J].中国血液流变学杂志,1999,9(3)：133-136.
[142]张朝云,叶红英,俞茂华,等.黄芪多糖对糖尿病大鼠心肌超微结构的影响[J].复旦学报,2001,28(6)：476-478.
[1]陆再英.内科学[M],第七版,北京：人民卫生出版社,2008：274-284.
[2]陶寿淇.我国心血管病及其危险因素近年演变趋势[J].中华心血管杂志,1999,27(4)：710.
[3]李艳,黄从新.重要炎性因子在冠心病病理过程中的作用[J].微循环杂志,2004,14(1)：47-49.
[4]霍雷.医学数据挖掘[M].高等教育出版社,北京：2006,123-126.
[5]邢向晖,陈鲁,张晓敏.中医证候规范化研究概要[J].中国中西医结合儿科学.2009,01：71-73.
[6]中西医结合防治冠心病、心绞痛、心律失常研究座谈会报道[J].医学研究通讯.1979,12：1-7.
[7]中国高血压防治指南修订委员会.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志2004.32(12)：1060-1063.
[8]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-419.
[9]Giovannucci E,Colditz G, Stamp fer MJ, et al. The asseasment of alcohol consumption by a simple self-administered questionnaire[J]. Am J Epidemmiol.1991.133::80-817.
[10]Santizo R, Anderson S, Ye S, et al.Effects of estrogen on leuko-cyte adhesion after transient forebrain ischemia[J].Stroke,2000,31:2231.
[11]Koh KK, Mincemoyer R, Bui MN. Effects of hormone menttherapy on fibrinolysis in postmenopausal women[J].N EnglMed,1997,336(4):683.
[12]Spyridopoulos L, Sullivan AB, Kearney M, et al. Estrogen-re-ceptior-mediated inhibition of human endothelial cell apoptosis:estradiol as survival factor[J].Circulation,1997,95(9): 1504.
[13]Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of17β-estradiol:require-ment for estradiol modification[J].Circulation,1997, 95(8):1378.
[14]Hong MK, Romm RA, Reagan K, et al. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery ease in postmenopausal woman[J].Am J Cardiol,1992,69(2):176.
[15]Barrett-Connor E, Grady D. Honnone replacement therapy, heart disease, and other consideration[J].Annu Rev Public Health,1998,19(1):55.
[16]Hirsch AT. Vascular disease. Hipertention, and prevention:from endothelium to clinical events[J]. JACC,2003,42(2):37-39.
[17]Vinik AL, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes [J]. Diabetes Care,2001,24(8):1476-1485.
[18]Weintraub WS, Daniels SR, Burke LE, et al. Value of Primordial and Primary Prevention for Cardiovascular Disease:A Policy Statement From the American Heart Associa-tion[J]. Circulation,2011,124(8):967-990.
[19]沙吉旦阿不都热衣木,热娜古丽·艾则孜,金伟,等.冠心病患者血栓前状态分子标志物检测[J].科技导报2009,27(1)：46-48.
[20]朱世明,吕以杰,白雪,等.老年心绞痛患者细胞粘附分子测定及调脂治疗观察[J].实用老年医学.2001,15(6)：314-315.
[21]刘红梅.冠心病患者血浆OX-LDL. NO、ICAM-1及VCAM-1水平测定及结果分析[J].吉林：吉林大学.2004：13-20.
[22]王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报.2006,30(1)：6-7.
[23]郭蕾,张启明,王永炎,等.证候规范化研究的思路和方法探讨[J].中国中西医结合杂志,2006,3(26)：258-261.
[24]陈贵延,薛赛琴,最新国内外疾病诊疗标准[M].第1版.北京：学苑出版社,1992：209-212,678-686.
[25]中华人民共和国卫生部,中药新药临床研究指导原则：第1辑[SJ.1993：41.
[26]沈绍功.诊治冠心病的新思路[J].中国中医急症,1999,8(2)：51.
[27]郭志华.冠心病心纹痛2432例中医辨证分型综合统计分析[J].湖南中医杂志,1998,14(2)：7-8.
[28]张秋雁,邓冰湘.冠心病心纹痛临床中医证型分布的回顾性分析[J].中医研究,2005,18(11)：23-24.
[29]李晋宏.213例冠心病中医辨证分型研究[J1.陕西中医,2004,27(2)：149-150.
[30]邢雁伟,王阶,衷敬柏,等.采用聚类分析和对应相关方法研究1069例冠心病心纹痛证候应证组合规律[J].中华中医药杂志,2007,22(11)：747-750.
[31]张明雪,曹洪欣,常艳鹏.冠心病(稳定性心纹痛)证候演变规律研究[J].中华中药杂志,2010,25(1)：24-27.
[32]何光明.“阳虚热象”浅析[J].中国中医基础医学杂志.2010,6(11)：987-989.
[33]徐慧聪,宋光辉,沈嫱,等.慢性心力衰竭气虚证、气阴两虚证、气阳虚证的临床特点[J].中西医结合心脑血管病杂志,2011,10：1155-1157.
[34]汤预生,张维福.变异性心绞痛的中医治疗[J].山东医药.2002,3：14-15.
[35]连叶琴,张昱,李殿芳.益气温阳活血治疗冠心病心绞痛临床观察[J].中华医药杂志,2006,6(8)：36-38.
[36]何强.步长脑心通胶囊对气虚血瘀气滞证的临床运用体会[J].中外健康文摘,2011,21：35-37.
[37].胡东斐.胸痹证治文献研究[J].山东中医药大学学报,2005,29(1)：37-40.
[38]洪永敦,黄衍寿,陈宇鹏,清热化痰活血法治疗冠心病不稳定性心绞痛临床研究[J].辽宁中医杂志,2005,32(7)：625-627.
[39].吴旸,王轩,崔杰,等.348例冠心病患者中医证候特点因子分析[J].中华中.医药学刊,2009,27(2)：392-394.
[40]李晓,丁书文,姜萍.心和颗粒剂保护冠心病患者血管内皮损伤的临床研究[J],中医杂志,2000,41(11)：661-662.
[41]卢笑晖.黄连解毒胶囊治疗不稳定性心绞痛临床疗效及作用机制研究[J].山东中医药大学学报.2005.29(6)：457-458.
[42]王长荣.“气虚生热”探源[J].中医药通报,2009.8(4)：32-33.
[43]陶克文.胸痹心痛证治体会[J].实用中医药杂志,1994,(3)：3.
[44]石刚,刘婷,程丑夫.冠心病常见证候临床流行病学调查[J].中华中医药学刊,2007,25(8)：1675-1676.
[45]吴辉,于扬文,吴伟,等.116例冠心病患者中医证候及病因分析[J].江苏中医药,2004,25(10)：30-31.
[46]1980年全国冠心病辨证论治研究座谈会.冠心病中医辨证试行标准[J].中医杂志,1980,21(8)：46.
[47]中西医结合学会心血管专业委员会.冠心病中医辨证标准[J].中西医结合杂志,1991,11(5)：257.
[48]张琳,于鑫婷,徐浩.冠心病中医证候特点的分析与思考[J].中西医结合心脑血管病杂志,2009,7(5)：578-550.
[49]王永霞,胡宇才,朱明军,等.冠心病心纹痛中医证候分布相关性研究[J].世界中西医结合杂志,2008,39。2)：714-716.
[50]王阶,李军,姚魁武,等.冠心病心绞痛证候要素与应证组合研究[J].中医杂志,2007,48(10)：920-922.
[51]贾振华,王永军,吴以岭,等.基于嫡的复杂系统分划方法与冠心病心绞痛证候要素提取及其分布规律[J].第二军医大学学报2007,28(7)：775-777.
[52]CarterAM, AnagnostoPoulouK, MansfieldMW, etal. Soluble P-selectin levels, P-selectin Polymorphisms and cardiovascular disease[J]. J Thromb Haemost,2003,1:1718-1723.
[53]Atalar E, Aytemir K, Haznedaroglu I et al. Increased Plasma levels of soluble selections in Patients with unstable angina[J]. Int J Cardiol,2001,78:69-73.
[54]Michelson AD, Barnard MR, Krueger LA, et al. Flow cytometry In:Miehelson AD, ed. Platelets, San Diego, Cali[J]. Academic Press,2002,297-315.
[55]Ley K, Huo Y. VCAM-1 is critical in atheorselcorsis[J]. J Clin Invest,2001,107(10): 1209-1210.
[56]Cyblky MI, Iiyama K, LI H, et al. Amajlor VCAM-1, but not ICAM-1, in early atheorceleorsis[J]. J Clin Invest,2001,107(10):1255-1262.
[57]Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. MaeroPhages infiltration in acute coronary syndromes:ImPlieations for Plaque ruP-ture[J]. Circulation.1994,90:775-778.
[58]杨欣,任卫东,马娜·动脉粥样硬化兔血管内皮功能与黏附分子ICAM-1表达关系的研究[J],中国现代医学杂志,2007,17(3)：309-311.
[59]曾知恒,吴海珊·急性冠脉综合征病人血清sCD40L和血浆sIL-AM-1、sE-selectin关 系的研究[J].广西医学,2004,26(11)：1592-1593
[60]张京春.陈可冀院士治疗冠心病心绞痛学术思想与经验[J].中西医结合心脑血管病杂志,2005,3(7)：634-636.
[61]黄献平,袁肇凯,毛以林,等.冠心病血疲证凝血功能指标的检测分析[J].中华医学与健康,2005,5：1-3.
[62]Shebuski RJ, Kilgore KS.Role of inflammatory mediators in thormbogene-sis[J]. Phamracol Exp Ther,2002,300(3):729-735.
[63]Kabbani S S, Watkins MW, Holoeh P A, et al. Platelet reaetivity in coronary ostial blood: A refleetion of the thrombotic state accom Panying Plaque rupture and of the adequaey of an-tithrombotic therapy[J]. J Thromb Thrombolysis,2001,12:171-176.
[64]梁知,顶志兵,顾仁越.冠心病中医证型与P-选择素相关性的临床研究[J].辽宁中医杂志,2006,33(12)：1595-1596.
[1]陈灏珠.实用心脏病学第四版[M].上海科学技术出版社,上海：2007,858-910.
[2]Alcaide P, Auerbach S, Luscinskas FW. Neutrophil Recruitment under Shear Flow:It's All about Endothelial Cell Rings and Gaps[J]. Microcirculation,2008,16(1):43-57.
[3]Christopher P, Baines and Jeffery D, Molkentin. STRESS signaling pathways that modulate cardiac myocyte apoptosis[J]. J Mol Cell Cardiol,2005,38(1):47-62.
[4]Zernecke A, Erl W, Fraemohs L, et al. Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from IkappaB-alpha kinase inhibition and cell death induction[J]. FASEB J,2003,17(9):1099-1101.
[5]Sun B, Fan H, Honda T, Fujimaki R, et al. Activation of NF kappa B and expression of ICAM-1 in ischemic-reperfused canine myocardium[J]. J Mol Cell Cardiol,2001,33(1): 109-19.
[6]罗瑛,谢秀梅,刘惠霞.急性冠状动脉综合征患者单核细胞核因子-KB活性变化与可溶性细胞间黏附分子-1的关系[J].中华老年心脑血管病杂志,2003,5(6)：379-380.
[7]Kurebayashi S, Xu X, Ishii S, et al. A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vas-cular endothelial cells[J]. Atherosclerosis,2005,182(1):71-77.
[8]谭杰雄,石巍,廖爱军,等.PDTC对重症急性胰腺炎胰腺腺泡细胞NF-kB活性与血液炎症因子的影响[J].临床消化病杂志,2007,19(3)：147-149.
[9]张波,王志农,王军,等.NF-κB在早期心肌缺血再灌流损伤中的作用[J].中华急诊医学杂志,2005,14(5)：384-385.
[10]潘波,杨成明,曾春雨,等.吡咯烷二硫代氨基甲酸盐对大鼠缺血性心肌损伤后心室扩张及心衰的干预效应[J].第三军医大学学报,2008,30(22)：2128-2130.
[11]Lin FS, Lin CC, Chien CS, et al. Involvement of p42/p44 MAPK, JNK, and NF-kappaB in IL-1beta-induced ICAM-1 expression in human pulmonary epithelial cells[J]. J Cell Phy-siol,2005,202(2):464-473.
[12]Lin WN, Luo SF, Lee CW, et al. Involvement of MAPKs and NF-kappaB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells[J]. Cell Signal, 2007,19.
[13]Nizamutdinova IT, Oh HM, Min YN, et al. Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endo-thelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways [J]. Int Immunopharmacol,2007,7(3):343-50.
[14]Taro M, Ingela T, Majlis B, et al. p38MAP Kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis[J]. J Cell Biology,2002,156(1):149-160.
[15]MU Jin-ye, CHEN Xiao-Guang. The progress of the study on the mitogen-activated protein kinase pathways[J]. Chin Bull Life Sci,2002,14(4):208-211.
[16]Kim H. P, Wang X, Zhang J, et al. Heat shock protein-70 mediates the cytoprotective effect of carbon monoxide:involvement of p38{beta} MAPK and heat shock factor-1[J]. J Immunol,2005,175(4):2622-2629.
[17]Kuma Y, Sabio G, Bain J, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo[J]. J Biol Chem,2005,280(20):19472-19479.
[18]Wang Y, Huang S, Sah V, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family [J]. J Biol Chem, 1998,273(4):2161-2168.
[19]Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress:the p38 MAPK pathway [J]. Crit Care Med,2000,28(1):67-77.
[20]Hajime Otani, et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the devel-opment of heart failure in the cardiomyopathic hamster[J]. Cardiovascular Research,2006, 69:888-898.
[21]Carsten Tschope, et al. Chronic inhibition of p38MAPK improves cardiac and endo-thelial function in experimental diabetes mellitus[J]. European Journal of Pharmacology, 2007,554:40-45.
[22]Winter R. J, Tijssen J. G. P, W'indhausen F, et al. A major determinant of C-reactive protein production in patients with acute coronary syndromes undergoing PCI:the p38 mito-gen activated protein kinase signalling pathway[J]. American Heart Association Scientific Sessions.2005.
[23]Weisman M. Double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase inhibitor, in patients with rheumatoid arthritis (RA) [J]. Ann. European Congress Rheumatol,2002.
[24]韩娟,刘宏艳,黄芪活血功效刍议[J].云南中医中药杂质.2008,29(3)：21-23.
[25]张灼,陈立新,宋崇顺等.黄芪多糖对大鼠心肌缺血-再灌注损伤后的保护作用[J].中国中医药信息杂志,2007,14(2)：33-34.
[26]Wu Yong, Shi Xian Shui, Wang Shi shun, et al. protective role of astragalus polysaccha-ride on endothelium cells induced by atherosclerosis[J]. rehabilitation of traditional Chinese medicine,2005,9(23):238-240.
[27]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[28]朱海燕,陈立新,朱陵群.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子-κB表达的影响[J].辽宁中医杂志,2008,35(1)：7-9.
[29]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[2]Atherosclerosis as an Inflammatory Disease. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis-an inflammation disease[J]. Curr Pharm Des,201229:115-126.
[3]李艳,黄从新.重要炎性因子在冠心病病理过程中的作用[J].微循环杂志,2004,14(1)：47-49.
[4]李守贵.ACS患者血清sICAM-1、sVCAM-1、可溶性P选择素的水平变化及意义.山东医药,2009,49(17)：84.
[5]暴清波,贾永平,吕吉元,等.IMA、P选择素和hs-CRP联合检测对早期诊断不稳定性心绞痛的作用研究[J].中西医结合心脑血管病杂志.2010,8(6)：657-659.
[6]孙丽,郭晓玲.冠心病患者血清E-选择素和Ox-LDL的测定及意义[J].包头医学院学报,2008,24(6)：580-581.
[7]韩学杰.沈绍功教授从痰论治冠心病经验[J].中国中医急症,2004,13(1)：31.
[8]Carter YM, Thomas R, Bargatze R, et al. Intracoronary E-/L-selectin blockade reduces neutrophil infiltration in heart transplantation[J]. Ann Thorac Surg,2002,74(6):2064-2070.
[9]Duda M, Czarnowska E, Kurzelewski M, et al. Ischemic preconditioning prevents endothelial dysfunction, P-selectin expression, and neutrophil adhesion by preventing en-dothelin and 02-generation in the post-ischemic guinea-pig heart. [J]. J Physiol Pharmacol, 2006,57(4):553-69.
[10]Hamaad A, Sosin MD, Blann AD, et al. Markers of Thrombosis and Hemostasis in Acute Coronary Syndromes:Relationship to Increased Heart Rate and Reduced Heart-Rate Varia-bility[J]. Clin Cardiol,2009,32(4):204-209.
[11]Golias C, Tsoutsi E, Matziridis A, et al. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. [J]. In Vivo,2007,21(5): 757-69.
[12]Ley K. The role of selectins in inflammation and disease[J]. Trends Mol Med,2003, 9(6):263-8.
[13]林琦,覃家锦,冯旭.P-选择素与体外循环关系的研究进展[J].微创医学,2009,4(2)：165-167.
[14]Alcaide P, Auerbach S, Luscinskas FW. Neutrophil Recruitment under Shear Flow: It's All about Endothelial Cell Rings and Gaps[J]. Microcirculation,2008,16(1):43-57.
[15]Shebuski RJ, Kilgore KS. Role of Inflammatory Mediators in Thrombogenesis [J]. J. Pharmaeol Exp Ther,2002,300(3):729-735.
[16]Libby P. Changing concepts of atherogenesis[J]. J Intern Med,2000,247(3):349-58.
[17]Dewberry R, Holden H, Crossman D, et al. Interleukin-Ireceptor antagonist expression in human endothelial eell and atherosclerosis [J]. Arterioscler Thromb Vase Biol,2000、20: 2394.
[18]Jia G, Aggarwal A, Tyndall SH, et al. Tumor necrosis factor-α regulates p27 kip expression and apoptosis in smooth muscle cells of human carotid plaques via forkhead tran-scription factor O1 [J]. Exp. Mol. Pathol,2001,90(1):1-8.
[19]Dietrich T, Hucko T, Schneemann C, et al. cal delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells[J]. Atherosclerosis,2011,220(2):329-36.
[20]Blann AD, Draper Z. Platelet activation as a marker of heart attack. [J]. Clin. Chim Acta,2011,412(11-12):841-2.
[21]Koyama H, Maeno T, Fukumoto S, et al. Platelet P-Selectin Expression Is Associated With Atherosclerotic Wall Thickness in Carotid Artery in Humans Circulation[J].2003,108: 524.
[22]Haverslag R, Pasterkamp G, Hoefer IE. Targeting adhesion molecules in cardiovascular disorders[J].Cardiovascular & hematological disorders drug targets,2008,8(4):252-60.
[23]Chen F, Castranova V, Shi X.New insights into the role of nuclear factor-kappaB in cell growth regulation[J]. Am J Pathol,2001,159(2):387-397.
[24]Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human vronchial epithelial cells by a NFkb ERK-dependent mechanism[J]. Eur J Pharmacol, 2008,582:145-153.
[25]Christopher P, Baines and Jeffery D, Molkentin. STRESS signaling pathways that modulate cardiac myocyte apoptosis[J]. J Mol Cell Cardiol,2005,38(1):47-62.
[26]刘杰,阚丹.Ⅰκκ/ⅠκB/NF-κb信号通路阻断及临床应用.实用医学杂志,2008,24(23)：4147-4149.
[27]Wang T, Zhang X, Li JJ. The role of NF-kappaB in the regulation of cell stress res-ponses. [J]. Int. Immunopharmacol,2002,2(11):1509-20.
[28]Chen YH, Lin SJ, Chen JW, et al. Magnolol attenuates VC AM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits[J]. Br J Pharmacol,2002,135(1):37-47.
[29]Squadrito F, Deodato B, Squadrito G, et al. Gene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury[J]. Lab Invest,2003,83(8): 1097-1104.
[30]Yeh CH, Lin YM, Wu YC, et al. Inhibition of NF-kappa B activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proin-flammatory gene up-regulation and matrix metalloproteinase expression[J]. J Cardiovasc Pharmacol,2005,45(4):301-9.
[31]Temming K, Lacombe M, van der Hoeven P, et al. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells:development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(Ⅱ)-based drug linker technolo-gy[J]. Bioconjug Chem,2006,17(5):1246-1255.
[32]Frenette PS, Denis CV, Weiss L, et al. p-Selectin Glycoprotein Ligand 1(PSGL-1)Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vi-vo[J]. J. Exp. Med,2000,191:1413-1422.
[33]Carter AM, Anagnostopoulou K, Mansfield MW, et al. Soluble p-selectin levels, P-selectin polymorphisms and cardiovascular disease[J]. J Thromb Haemost,2003,1(8): 1718-1723.
[34]Barbaux SC, Blankenberg S, Rupprecht HJ, et al. Association between P selectin gene polymorphisms and soluble p-selectin levels and their relation to coronary artery disease[J]. Arterioscler Thromb Vase Biol,2001,21(10):1668-1673.
[35]Antoniades C, Bakogiannis C, Tousoulis D, et al. Platelet activation in atherogenesis associated with low-grade inflammation[J]. Inflamm Allergy Drug Targets,2010,9(5): 334-45.
[36]陈宇杰,陆信武.P-选择素与动脉粥样硬化形成[J].国外医学,生理病理科学与临床分册,2002,22(4)：323-325.
[37]Blake GJ, Ridker PM. Novel ciinical markers of vascular wall inflammation[J]. Circ Res,2001,89(9):763-771.
[38]Dong ZM, Brown AA, Wagner DD. Prominent role of p-selectin in the development of advance atherosclerosis in apoE-deficient mice[J]. Circulation,2000,101:2290-2295.
[39]Russo HM, Wickenheiser KJ, Luo W, et al. P-selectin glycoprotein ligand-1 regulates adhesive properties of the endothelium and leukocyte trafficking into adipose tis-sue[J]. Circ. Res,2010,107(3):388-97.
[40]Phillips JW, Barringhaus KG, Sanders JM, et al. Single Injection of p-Selectin or p-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Blocks Neointima Formation After Arterial Injury in Apolipoprotein E-Deficient Mice[J]. Circulation,2003,107(17): 2244-2249.
[41]Kabbani SS, Watkins MW, Holoch PA, et al. Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of an-ti-thrombotic therapy [J]. J Thromb ThrombolysiS,2001,12(2):171-176.
[42]Atalar E, hytemir K, Haznedaroglu I, et al. Increased plasma levels of soluble selectins in patients with unstable angina[J]. Int J Cardiol,2001,78(1):69-73.
[43]Kayikcioglu M, Can L, Mete-Erdem N, et al. Soluble p-selectin and the Success of thrombolysis in acute myocardial infarction[J]. Int J Cardiol,2001,79(2-3):223-229.
[44]Wang J, Zhang S, Jin Y, et al. Elevated levels of plat el et-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome[J]. Int. J. Cardiol, 2007,115(3):361-5.
[45]Zhang SZ, Jin YP, Qin GM, et al. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes[J]. Clin Cardiol,2007,30(1):26-31.
[46]Merten M, Thiagarajan P. p-selectin expression on platelets determines size and stability of platelet aggregates [J]. Circulation,2000,102(16):1931-1936.
[47]Burger PC and Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion devel-opment[J]. Blood,2003,101(7):2661-2666.
[48]于涛,曹洪欣.胸痹(冠心病)证候演变规律的临床研究[J].中医药信息,2004,21(3)：44.
[49]马晓昌,尹太英,陈可冀,等.冠心病中其分型冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(4)：254.
[50]Daniel M, Jr. DVM, Diana Farris LVT, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis[J]. J Surg Res,2002,108(2):212-221.
[51]Rossi B, Constantin G. Anti-selectin therapy for the treatment of inflammatory diseas-es[J]. Inflamm Allergy Drug Targets,2008,7(2):85-93.
[52]Blann A D, McCollum C N, Lip G Y. Relationship between plasma marker of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals[J]. Blood Coagulation & Fibrinolysis,2002,13:513.
[53]Kerner T, Ahlers O, Reschreiter H, et al. Adhesion molecules in different treatments of acute myocardial infarction[J]. Crit Care,2001,5(3):145-50.
[54]Sukhotnik I, Coran AG, Greenblatt R, et al. Effect of 100% oxygen on E-selectin expression, recruitment of neutrophils and enterocyte apoptosis following intestinal ische-mia-reperfusion in a rat[J]. Pediatr. Surg. Int,2008,24(1):29-35.
[55]Zarbock A, Ley K, McEver RP, et al. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow[J]. Blood,2011, 118(26):6743-51.
[56]Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease[J]. J Cardiol,2009,53(3):317-33.
[57]韦叶生,李艳,张平安,等.E-选择素A561C基因多态性与老年人不稳定心绞痛的相关性研究[J],中国老年学杂志,2003,23(10)：651-653.
[58]Zheng F, Chevalier J A, Zhang L Q, et al. An Hphl polymorphism in the E-selectin gene is associated with premature coronary artery disease[J]. Clin Genet,2001,59:58.
[59]Kavsak PA, Ko DT, Newman AM, et al. Upstream markers provide for early iden-tification of patients at high risk for myocardial necrosis and adverse out-comes[J]. Clin. Chim. Acta,2008,387(1-2):133-8.
[60]杨立森,林媛豪,石学宁,等.可溶性E选择素对冠心病心绞痛的诊断意义[J].临床心血管病杂志,2003,19(5)：272-274.
[61]Nusca A, Melfi R, Di Sciascio G. Percutaneous coronary interventions and statins therapy. [J]. Therapeutic advances in cardiovascular disease,2008,2(2):101-7.
[62]Lee JK, Kim JK, Park SH, et al. Lactosylceramide Mediates the Expression of Adhesion Molecules in TNF-a and IFNy-stimulated Primary Cultured Astrocytes[J]. Korean J. Physiol. Pharmacol,2011,15(5):251-8.
[63]Pietruczuk M, Pietruczuk A, Pancewicz S, et al. ICAM-1:structure, biological role and clinical significance[J]. Pol. Merkur. Lekarski,2004,17(101):507-11.
[64]金伯泉.细胞和分子免疫学(第二版)[M].北京：科学出版社,2003：34-386.
[65]Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease[J]. J Cardio,2009,53 (3):317-33.
[66]Wittchen ES. Endothelial signaling in paracellular and transcellular leukocyte transmi-gration[J]. Front. Biosci,2009,14:2522-45.
[67]Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human athe-rosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transen-dothelial migration[J]. Circ. Res.2011,108(3):335-43.
[68]Stephanie A, Camacho, William R, et al. A key rote for ICAM-1 in generating effeetor cells mediating inflammatory responses[J]. Nature Immunology,2001,2:523-529.
[69]Lawson C, Wolf S. ICAM-1 signaling in endothelial cells[J]. Pharmacol Rep,2009, 61(1):22-32.
[70]Rohlena J, Volger OL, van Buul JD, et al, Endothelial CD81 is a marker of early human atherosclerotic plaques and facilitates monocyte adhesion[J]. Cardiovasc. Res,2008,81(1): 187-96.
[71]Paessens LC, Singh SK, Fernandes RJ, et al. Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) provide co-stimulation in posi-tive selection along with survival of selected thymocytes[J]. Mol. Immunol,2008,45(1): 42-8.
[72]Nachtigal P, Kopecky M, Solichova D, et al. The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis[J]. J. Pharm. Pharmacol,2005,57(2):197-203.
[73]Combe C, Burton CJ, Dufourco P, et al. Hypoxia induces intercellular adhesion molecule-lon cultured human tubular cells[J]. Kidney Int,1997,51(6):1703-1709.
[74]Yamanashi Y, Mori M, Terajima K, et al. A transient inflammatory reaction in the lung after experimental hemorrhagic shock and resuscitation with a hemoglobin-vesicles solution compared with rat RBC transfusion[J]. ASAIO J,2009,55(5):478-83.
[75]Behnam SM, Behnam SE, Koo JY, et al. TNF-alpha inhibitors and congestive heart failure[J]. Skinmed,2005,4(6):363-8.
[76]Wang Y, Zhou Y, Meng L, et al. Inflammatory Mediators in Chinese Patients With Congestive Heart Failure[J]. J Clin Pharmacol,2009,49(5):591-9.
[77]罗成基,裴雪涛主编.造血微环境[M].北京：世界医药出版社,2001,1-50.
[78]司英健,张曦,陈幸华,等.VCAM-1和EGFP双基因共表达重组腺病毒的构建[J].重庆医学,2007,36(17)：1699-1703.
[79]Vcerans C, Van Hennik PB, vander Schoot CE. Homing of human hematopoiefic stem and progenitor cells:new insights, new challenges[J]. Hematother Stem Cell Res,2001, 10(6),725-738.
[80]Lapidot T, Dar A, Kollet O. How do stem cells find their way home[J]. Blood,2005, 106(6),1901-1910.
[81]张丽慧,魏尔清.ICAM-1、VCAM-1在脑缺血损伤炎症机制中的作用及调控[J].中国药理学通报,2005,21(11)：1281-1282.
[82]洪永敦,朱会英,陈宇鹏,等.冠心病痰瘀证候与E选择素G98T及S128R基因多态性的关系研究[J].广州中医药大学学报,2009,26(1),1-4.
[83]骆丽娟.冠心病证型与P-选择素、TXB2及6-Keto-PGF1α含量变化关系的研究[J].上海中医药杂志,2002,7,13-14.
[84]林桂永,王子健.冠心病血瘀证气血辨证与内皮细胞损伤的关系[J].中西医结合心脑血管病杂志,2005,3(10),856-858.
[85]柏正平,谭光波,卜献春,等.冠心病中医辨证分型与细胞黏附分子的关系[J].中西医结合心脑血管病杂志,2006,4(2),108-109.
[86]王锡煌,王挹青.血管生成素1通过NF-kB传导通路影响内皮祖细胞炎症反应中黏附分子的表达[J].中国动脉硬化杂志,2011,3：140-141.
[87]庄梅,方颖,吴立荣,等.地塞米松对大鼠缺血再灌注心肌细胞凋亡及HSP72、 NF-kB表达的影响[J].中国老年学杂志.2008,15：1467-1469.
[88]杨慎先,万大国,杜诗兵.瑞舒伐他汀对急性心肌梗死大鼠NF-kB和IL-6表达的影响[J].心脏杂志,2011,04：151-142.
[89]潘金生,刘应才,陈辉,等.阿托伐他汀钙对扩张型心肌病患者促炎性细胞因子表达和NF-KB/p65活化的影响[J].中国心血管杂志,2007.2：114-117.
[90]姜希娟,杜云,苏金玲,等.心脑血脉宁对家兔易损斑块模型血脂NF-kB和ICAM-1 mRNA表达的影响[J].辽宁中医杂志,2008,5：783-785.
[91]杨萍,周玉平.缺血再灌注心肌EPOR的表达调控及丹参酮ⅡA的干预作用[J].辽宁中医杂志,2012,1：70-72.
[92]尹梅,高海青,李保应.通心络对糖尿病大鼠心肌RAGE、NF-kB的影响[J].山东大学学报(医学版),2011,8：68-72.
[93]贾钰华,周玉平,陈育尧,等.定心方对大鼠缺血及再灌注心律失常的保护作用及对核因子κB活化的影响[J].中医杂志,2007,4：35-39.
[94]李向东,肖骅,覃数,等.辛伐他汀调节p38和CARP与改善心肌重塑的关系[J].中国药学杂志,2009,11：100-102.
[95]郑晓丹,严世芸,秦仲君.通心脉方对大鼠心肌缺血再灌注损伤AKt及p38αMAPK蛋白表达的影响[J].中医研究.2011.6：47-49.
[96]尹慧秋,张继东,林海青,等.舒脉胶囊改善心肌梗死大鼠左室重构与心功能的研究[J].山东中医药大学学报,2008,2：790-791.
[97]Han J, Kamber M. Data Ming. Concepts and Techniques[J]. Morgan Kaufmann Publishers,2000,5-14.
[98]吴凤娟,刁永峰.浅谈数据挖掘技术[J].乐山师范学院学报,2004,19(12)：96.
[99]薛薇,陈欢歌.Clementine数据挖掘方法及应用[M].电子工业出版社.北京.2010：120-180.
[100]崔雷.医学数据挖掘[M].高等教育出版社,北京,2006：56-69.
[101]薛薇,陈欢歌.Clementine数据挖掘方法及应用[M].电子工业出版社.北京.2010：271-301.
[102]刘仁权.SPSS统计软件[M].中国中医药出版社.北京：163-170.
[103]周晓宏,郭文静.探索性因子分析与验证性因子分析异同比较[J].科技和产业.2008.8(9)：69-71.
[104]张家放.医用多元统计方法[M].武汉：华中科技大学出版社,2002：323-338.
[105]赵铁牛,王泓午,刘桂芬.验证性因子分析及应用[J].中国卫生统计.2010,27(6)：608-609.
[106]宋毅,裴建,刘志丹,等.针刺干预缺血性中风病证候动态化及相关研究[J].中西医结合学报,2009,4：334-341.
[107]李晓宇.基于支撑向量机的中医舌色苔色识别算法研究[J].北京生物医学工程,2006,25(1)：43-46.
[108]瞿海斌,毛利锋,王阶.基于决策树的血瘀证诊断规则自动归纳方法[J].中国生物医学工程学报,2005,24(6)：709-711,727.
[109]徐蕾,贺佳,孟虹.基于信息熵的决策树在慢性胃炎中医辨证中的应用[J].第二军医大学学报,2004,25(9)：1009-1012.
[110]林维鉴.BP网络用于中医痹证证候分类[J].福建中医学院学报,1997,7(4)：41-43.
[111]胡随瑜,唐风英,喻长远,等.前馈反向传播网络在抑郁症中医证型分类中的初步研究[J].中医杂志,2004,45(7)：532-533.
[112]杜文斌.基于神经网络的冠心病证候诊断标准与药效评价模型研究[D].沈阳：辽宁中医学院,2004：4-5.
[113]张明雪,曹洪欣,常艳鹏,等.论“寒邪”在冠心病发病中的作用[J].中医药学报.2009,3：710-715.
[114]唐启盛,曲淼,包祖晓,等.抑郁症中医证候的贝叶斯网络研究[J].中医杂志,2008,49(11)：1013-1015.
[115]宓余强,伍喜良,曹武奎,等.72例慢性乙型重型肝炎症状与舌脉象聚类分析[J].传染病信息,2010,5：276-278.
[116]王阶,何庆勇,基于聚类分析和对应分析的稳定型心绞痛证候要素组合规律的研究[J].中西医结合学报.2008,7：690-694.
[117]陈建设,陈文垲.胃炎(胃脘痛)的证候聚类分析[J].辽宁中医杂志.2007,34(3)：292-293.
[118]王嘉麟,郭蓉娟,张允岭,等.基于因子分析的高血压病证候要素研究[J].天津中医药,2010,5：434-436.
[119]龚燕冰,罗增刚,高思华,等.运用因子分析方法探索2型糖尿病证候要素及其靶位特征[J].中医杂志,2011,52(13)：1102-1103.
[120]邹蔚萌,崔方圆,龙子弋,等.基于数据挖掘的缺血性中风火热证变化特征分析[J].辽宁中医杂志,2011,38(6)：1042-1044.
[121]陈明,杨慧芳,余蕾.基于关联规则的肝硬变辨证数据挖掘研究[J].河南中医,2009,29(3)：258-260.
[122]黄小波,李宗信,陈文强,等.慢性疲劳综合征气虚与血虚病机关系的定量分析.中国中医药科技,2007,14(1)：3-5.
[123]王伽伯,赵海平,肖小河,等.基于“有故无殒”思想和因子分析的大黄量-效(毒)关系研究[C].2010年中国药学大会暨第十届中国药师周论文集,2010,11：1-10.
[124]李续娥,张敏,李小梅,等.归胃经寒性中药对胃热证大鼠全身及胃机能影响的因子分析模型[J].生物数学学报,2008,4：25-27.
[125]何前锋,周雪忠,周忠眉,等.基于中药功效的聚类分析[J],中国中医药信息杂志,2004,11(6)：561-562.
[126]孙燕,臧佳新,任廷革.基于数据挖掘技术的医案整理方法探讨[J].中国中医药信息杂志,2006,13(11)：106-107.
[127]谭勇,吕爱平,车念聪,等.数据挖掘在中医学术流派研究中的应用[J].时珍国医国药,2007,18(12)：2990-2991.
[128]朱建贵,田琳,李平,等.基于信息和数据挖掘技术的名老中医临床诊疗经验研究思路[J].世界科学技术-中医药现代化,2005,7(1)：98-105.
[129]张灼,陈立新,宋崇顺,等.黄芪多糖对大鼠心肌缺血-再灌注损伤后的保护作用[J].中国中医药信息杂志,2007,14(2)：33-34.
[130]朱海燕,陈立新,朱陵群.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子-KB表达的影响[J].辽宁中医杂志,2008,35(1)：7-9.
[131]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[132]张灼,陈立新,宋崇顺,等.黄芪多糖对大鼠心肌缺血-再灌注损伤后的保护作用[J].中国中医药信息杂志,2007,14(2)：33-34.
[133]朱海燕,陈立新,朱陵群.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子-κB表达的影响[J].辽宁中医杂志,2008,35(1)：7-9.
[134]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[135]吴勇,欧阳静萍,涂淑珍,等.黄芪多糖对动脉粥样硬化内皮细胞损伤的影响[J].湖北中医学院学报,2002,4(1)：21.
[136]凌洪锋,苏丹,曹洋.黄芪多糖抗氧化作用研究[J].医学理论与实践,2005,18(8)：872-873.
[137]解慧梅,穆祥,胡格.黄芪多糖对大鼠肠黏膜微血管内皮细胞分泌NO的影响[J].北京农学院学报,2005,20(4)：58-61.
[138]Nathant C. Regulation of biosynthesis of nitric oxide[J]. Biol Chem,1994,269: 13725-13728.
[139]赵红卫,李晓玉.NO与免疫调节[J].上海免疫学杂志,1996,4(6)：373-376.
[140]魏毅,刘婷婷,林婷婷,等.黄芪多糖及其与白芍总苷协同对兔血小板聚集功能的影响魏[J].中国临床药理学与治疗学,2005,10(8)：932-934.
[141]许艳,高佩畸,梁庆成,等.黄芪多糖对脑血栓的疗效试验研究[J].中国血液流变学杂志,1999,9(3)：133-136.
[142]张朝云,叶红英,俞茂华,等.黄芪多糖对糖尿病大鼠心肌超微结构的影响[J].复旦学报,2001,28(6)：476-478.
[1]陆再英.内科学[M],第七版,北京：人民卫生出版社,2008：274-284.
[2]陶寿淇.我国心血管病及其危险因素近年演变趋势[J].中华心血管杂志,1999,27(4)：710.
[3]李艳,黄从新.重要炎性因子在冠心病病理过程中的作用[J].微循环杂志,2004,14(1)：47-49.
[4]霍雷.医学数据挖掘[M].高等教育出版社,北京：2006,123-126.
[5]邢向晖,陈鲁,张晓敏.中医证候规范化研究概要[J].中国中西医结合儿科学.2009,01：71-73.
[6]中西医结合防治冠心病、心绞痛、心律失常研究座谈会报道[J].医学研究通讯.1979,12：1-7.
[7]中国高血压防治指南修订委员会.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志2004.32(12)：1060-1063.
[8]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-419.
[9]Giovannucci E,Colditz G, Stamp fer MJ, et al. The asseasment of alcohol consumption by a simple self-administered questionnaire[J]. Am J Epidemmiol.1991.133::80-817.
[10]Santizo R, Anderson S, Ye S, et al.Effects of estrogen on leuko-cyte adhesion after transient forebrain ischemia[J].Stroke,2000,31:2231.
[11]Koh KK, Mincemoyer R, Bui MN. Effects of hormone menttherapy on fibrinolysis in postmenopausal women[J].N EnglMed,1997,336(4):683.
[12]Spyridopoulos L, Sullivan AB, Kearney M, et al. Estrogen-re-ceptior-mediated inhibition of human endothelial cell apoptosis:estradiol as survival factor[J].Circulation,1997,95(9): 1504.
[13]Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of17β-estradiol:require-ment for estradiol modification[J].Circulation,1997, 95(8):1378.
[14]Hong MK, Romm RA, Reagan K, et al. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery ease in postmenopausal woman[J].Am J Cardiol,1992,69(2):176.
[15]Barrett-Connor E, Grady D. Honnone replacement therapy, heart disease, and other consideration[J].Annu Rev Public Health,1998,19(1):55.
[16]Hirsch AT. Vascular disease. Hipertention, and prevention:from endothelium to clinical events[J]. JACC,2003,42(2):37-39.
[17]Vinik AL, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes [J]. Diabetes Care,2001,24(8):1476-1485.
[18]Weintraub WS, Daniels SR, Burke LE, et al. Value of Primordial and Primary Prevention for Cardiovascular Disease:A Policy Statement From the American Heart Associa-tion[J]. Circulation,2011,124(8):967-990.
[19]沙吉旦阿不都热衣木,热娜古丽·艾则孜,金伟,等.冠心病患者血栓前状态分子标志物检测[J].科技导报2009,27(1)：46-48.
[20]朱世明,吕以杰,白雪,等.老年心绞痛患者细胞粘附分子测定及调脂治疗观察[J].实用老年医学.2001,15(6)：314-315.
[21]刘红梅.冠心病患者血浆OX-LDL. NO、ICAM-1及VCAM-1水平测定及结果分析[J].吉林：吉林大学.2004：13-20.
[22]王永炎,张启明,张志斌.证候要素及其靶位的提取[J].山东中医药大学学报.2006,30(1)：6-7.
[23]郭蕾,张启明,王永炎,等.证候规范化研究的思路和方法探讨[J].中国中西医结合杂志,2006,3(26)：258-261.
[24]陈贵延,薛赛琴,最新国内外疾病诊疗标准[M].第1版.北京：学苑出版社,1992：209-212,678-686.
[25]中华人民共和国卫生部,中药新药临床研究指导原则：第1辑[SJ.1993：41.
[26]沈绍功.诊治冠心病的新思路[J].中国中医急症,1999,8(2)：51.
[27]郭志华.冠心病心纹痛2432例中医辨证分型综合统计分析[J].湖南中医杂志,1998,14(2)：7-8.
[28]张秋雁,邓冰湘.冠心病心纹痛临床中医证型分布的回顾性分析[J].中医研究,2005,18(11)：23-24.
[29]李晋宏.213例冠心病中医辨证分型研究[J1.陕西中医,2004,27(2)：149-150.
[30]邢雁伟,王阶,衷敬柏,等.采用聚类分析和对应相关方法研究1069例冠心病心纹痛证候应证组合规律[J].中华中医药杂志,2007,22(11)：747-750.
[31]张明雪,曹洪欣,常艳鹏.冠心病(稳定性心纹痛)证候演变规律研究[J].中华中药杂志,2010,25(1)：24-27.
[32]何光明.“阳虚热象”浅析[J].中国中医基础医学杂志.2010,6(11)：987-989.
[33]徐慧聪,宋光辉,沈嫱,等.慢性心力衰竭气虚证、气阴两虚证、气阳虚证的临床特点[J].中西医结合心脑血管病杂志,2011,10：1155-1157.
[34]汤预生,张维福.变异性心绞痛的中医治疗[J].山东医药.2002,3：14-15.
[35]连叶琴,张昱,李殿芳.益气温阳活血治疗冠心病心绞痛临床观察[J].中华医药杂志,2006,6(8)：36-38.
[36]何强.步长脑心通胶囊对气虚血瘀气滞证的临床运用体会[J].中外健康文摘,2011,21：35-37.
[37].胡东斐.胸痹证治文献研究[J].山东中医药大学学报,2005,29(1)：37-40.
[38]洪永敦,黄衍寿,陈宇鹏,清热化痰活血法治疗冠心病不稳定性心绞痛临床研究[J].辽宁中医杂志,2005,32(7)：625-627.
[39].吴旸,王轩,崔杰,等.348例冠心病患者中医证候特点因子分析[J].中华中.医药学刊,2009,27(2)：392-394.
[40]李晓,丁书文,姜萍.心和颗粒剂保护冠心病患者血管内皮损伤的临床研究[J],中医杂志,2000,41(11)：661-662.
[41]卢笑晖.黄连解毒胶囊治疗不稳定性心绞痛临床疗效及作用机制研究[J].山东中医药大学学报.2005.29(6)：457-458.
[42]王长荣.“气虚生热”探源[J].中医药通报,2009.8(4)：32-33.
[43]陶克文.胸痹心痛证治体会[J].实用中医药杂志,1994,(3)：3.
[44]石刚,刘婷,程丑夫.冠心病常见证候临床流行病学调查[J].中华中医药学刊,2007,25(8)：1675-1676.
[45]吴辉,于扬文,吴伟,等.116例冠心病患者中医证候及病因分析[J].江苏中医药,2004,25(10)：30-31.
[46]1980年全国冠心病辨证论治研究座谈会.冠心病中医辨证试行标准[J].中医杂志,1980,21(8)：46.
[47]中西医结合学会心血管专业委员会.冠心病中医辨证标准[J].中西医结合杂志,1991,11(5)：257.
[48]张琳,于鑫婷,徐浩.冠心病中医证候特点的分析与思考[J].中西医结合心脑血管病杂志,2009,7(5)：578-550.
[49]王永霞,胡宇才,朱明军,等.冠心病心纹痛中医证候分布相关性研究[J].世界中西医结合杂志,2008,39。2)：714-716.
[50]王阶,李军,姚魁武,等.冠心病心绞痛证候要素与应证组合研究[J].中医杂志,2007,48(10)：920-922.
[51]贾振华,王永军,吴以岭,等.基于嫡的复杂系统分划方法与冠心病心绞痛证候要素提取及其分布规律[J].第二军医大学学报2007,28(7)：775-777.
[52]CarterAM, AnagnostoPoulouK, MansfieldMW, etal. Soluble P-selectin levels, P-selectin Polymorphisms and cardiovascular disease[J]. J Thromb Haemost,2003,1:1718-1723.
[53]Atalar E, Aytemir K, Haznedaroglu I et al. Increased Plasma levels of soluble selections in Patients with unstable angina[J]. Int J Cardiol,2001,78:69-73.
[54]Michelson AD, Barnard MR, Krueger LA, et al. Flow cytometry In:Miehelson AD, ed. Platelets, San Diego, Cali[J]. Academic Press,2002,297-315.
[55]Ley K, Huo Y. VCAM-1 is critical in atheorselcorsis[J]. J Clin Invest,2001,107(10): 1209-1210.
[56]Cyblky MI, Iiyama K, LI H, et al. Amajlor VCAM-1, but not ICAM-1, in early atheorceleorsis[J]. J Clin Invest,2001,107(10):1255-1262.
[57]Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. MaeroPhages infiltration in acute coronary syndromes:ImPlieations for Plaque ruP-ture[J]. Circulation.1994,90:775-778.
[58]杨欣,任卫东,马娜·动脉粥样硬化兔血管内皮功能与黏附分子ICAM-1表达关系的研究[J],中国现代医学杂志,2007,17(3)：309-311.
[59]曾知恒,吴海珊·急性冠脉综合征病人血清sCD40L和血浆sIL-AM-1、sE-selectin关 系的研究[J].广西医学,2004,26(11)：1592-1593
[60]张京春.陈可冀院士治疗冠心病心绞痛学术思想与经验[J].中西医结合心脑血管病杂志,2005,3(7)：634-636.
[61]黄献平,袁肇凯,毛以林,等.冠心病血疲证凝血功能指标的检测分析[J].中华医学与健康,2005,5：1-3.
[62]Shebuski RJ, Kilgore KS.Role of inflammatory mediators in thormbogene-sis[J]. Phamracol Exp Ther,2002,300(3):729-735.
[63]Kabbani S S, Watkins MW, Holoeh P A, et al. Platelet reaetivity in coronary ostial blood: A refleetion of the thrombotic state accom Panying Plaque rupture and of the adequaey of an-tithrombotic therapy[J]. J Thromb Thrombolysis,2001,12:171-176.
[64]梁知,顶志兵,顾仁越.冠心病中医证型与P-选择素相关性的临床研究[J].辽宁中医杂志,2006,33(12)：1595-1596.
[1]陈灏珠.实用心脏病学第四版[M].上海科学技术出版社,上海：2007,858-910.
[2]Alcaide P, Auerbach S, Luscinskas FW. Neutrophil Recruitment under Shear Flow:It's All about Endothelial Cell Rings and Gaps[J]. Microcirculation,2008,16(1):43-57.
[3]Christopher P, Baines and Jeffery D, Molkentin. STRESS signaling pathways that modulate cardiac myocyte apoptosis[J]. J Mol Cell Cardiol,2005,38(1):47-62.
[4]Zernecke A, Erl W, Fraemohs L, et al. Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from IkappaB-alpha kinase inhibition and cell death induction[J]. FASEB J,2003,17(9):1099-1101.
[5]Sun B, Fan H, Honda T, Fujimaki R, et al. Activation of NF kappa B and expression of ICAM-1 in ischemic-reperfused canine myocardium[J]. J Mol Cell Cardiol,2001,33(1): 109-19.
[6]罗瑛,谢秀梅,刘惠霞.急性冠状动脉综合征患者单核细胞核因子-KB活性变化与可溶性细胞间黏附分子-1的关系[J].中华老年心脑血管病杂志,2003,5(6)：379-380.
[7]Kurebayashi S, Xu X, Ishii S, et al. A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vas-cular endothelial cells[J]. Atherosclerosis,2005,182(1):71-77.
[8]谭杰雄,石巍,廖爱军,等.PDTC对重症急性胰腺炎胰腺腺泡细胞NF-kB活性与血液炎症因子的影响[J].临床消化病杂志,2007,19(3)：147-149.
[9]张波,王志农,王军,等.NF-κB在早期心肌缺血再灌流损伤中的作用[J].中华急诊医学杂志,2005,14(5)：384-385.
[10]潘波,杨成明,曾春雨,等.吡咯烷二硫代氨基甲酸盐对大鼠缺血性心肌损伤后心室扩张及心衰的干预效应[J].第三军医大学学报,2008,30(22)：2128-2130.
[11]Lin FS, Lin CC, Chien CS, et al. Involvement of p42/p44 MAPK, JNK, and NF-kappaB in IL-1beta-induced ICAM-1 expression in human pulmonary epithelial cells[J]. J Cell Phy-siol,2005,202(2):464-473.
[12]Lin WN, Luo SF, Lee CW, et al. Involvement of MAPKs and NF-kappaB in LPS-induced VCAM-1 expression in human tracheal smooth muscle cells[J]. Cell Signal, 2007,19.
[13]Nizamutdinova IT, Oh HM, Min YN, et al. Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endo-thelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways [J]. Int Immunopharmacol,2007,7(3):343-50.
[14]Taro M, Ingela T, Majlis B, et al. p38MAP Kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis[J]. J Cell Biology,2002,156(1):149-160.
[15]MU Jin-ye, CHEN Xiao-Guang. The progress of the study on the mitogen-activated protein kinase pathways[J]. Chin Bull Life Sci,2002,14(4):208-211.
[16]Kim H. P, Wang X, Zhang J, et al. Heat shock protein-70 mediates the cytoprotective effect of carbon monoxide:involvement of p38{beta} MAPK and heat shock factor-1[J]. J Immunol,2005,175(4):2622-2629.
[17]Kuma Y, Sabio G, Bain J, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo[J]. J Biol Chem,2005,280(20):19472-19479.
[18]Wang Y, Huang S, Sah V, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family [J]. J Biol Chem, 1998,273(4):2161-2168.
[19]Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress:the p38 MAPK pathway [J]. Crit Care Med,2000,28(1):67-77.
[20]Hajime Otani, et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the devel-opment of heart failure in the cardiomyopathic hamster[J]. Cardiovascular Research,2006, 69:888-898.
[21]Carsten Tschope, et al. Chronic inhibition of p38MAPK improves cardiac and endo-thelial function in experimental diabetes mellitus[J]. European Journal of Pharmacology, 2007,554:40-45.
[22]Winter R. J, Tijssen J. G. P, W'indhausen F, et al. A major determinant of C-reactive protein production in patients with acute coronary syndromes undergoing PCI:the p38 mito-gen activated protein kinase signalling pathway[J]. American Heart Association Scientific Sessions.2005.
[23]Weisman M. Double-blind, placebo-controlled trial of VX-745, an oral p38 mitogen activated protein kinase inhibitor, in patients with rheumatoid arthritis (RA) [J]. Ann. European Congress Rheumatol,2002.
[24]韩娟,刘宏艳,黄芪活血功效刍议[J].云南中医中药杂质.2008,29(3)：21-23.
[25]张灼,陈立新,宋崇顺等.黄芪多糖对大鼠心肌缺血-再灌注损伤后的保护作用[J].中国中医药信息杂志,2007,14(2)：33-34.
[26]Wu Yong, Shi Xian Shui, Wang Shi shun, et al. protective role of astragalus polysaccha-ride on endothelium cells induced by atherosclerosis[J]. rehabilitation of traditional Chinese medicine,2005,9(23):238-240.
[27]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.
[28]朱海燕,陈立新,朱陵群.黄芪多糖对人心脏微血管内皮细胞缺氧再复氧损伤后核因子-κB表达的影响[J].辽宁中医杂志,2008,35(1)：7-9.
[29]陈立新,朱海燕,朱陵群,等.黄芪多糖对人心脏微血管内皮细胞增殖及再灌注后内皮细胞与中性粒细胞黏附的影响[J].中国组织工程研究与临床康复,2007,11(27)：5382-5386.